NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Dat e: April 8, 2013 
 
1 NCI Protocol #:  CITN06 -ALT -803 
 
Local Protocol #: CA-ALT -803-01-13 
 TITLE:  A Phase 1/2 Study of the Clinical and Immunologic E ffects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with Advanced Melanoma   
 
(Advanced Melanoma – ICD-10053571) 
         Sponsor:  
       
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson 
Cancer Research Center  
 *Principal Investigator:  [INVESTIGATOR_355332], MD  
 University of Washington, Seattle Cancer Care Alliance  
 [ADDRESS_442582] E, G4810 
 Seattle WA [ZIP_CODE] 
 Telephone: [PHONE_7368] 
 Fax: [PHONE_7369] 
 [EMAIL_6805]  
 Co-Investigators:  Adil Daud , MD 
 University of [LOCATION_004] San Francisco  
 ([PHONE_7370]  
 [EMAIL_6806]
 
  
 Marc Ernstoff, MD  
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7371] 
 [EMAIL_6807]   
  Thomas Waldmann, MD 
 National Cancer Institute  
 ([PHONE_7372] 
 [EMAIL_6808]
 
     
 
  Hing C. Wong, Ph.D.   Altor Bioscience Corporation.   Miramar, [LOCATION_012] [ZIP_CODE]   Telephone: [PHONE_7260]   Safety Data Fax:  [PHONE_7261] 
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Dat e: April 8, 2013 
 
2 INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1/2 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Melanoma  
   
Date of Protocol:   
Version # [ADDRESS_442583]:  
 
Hing C. Wong, Ph.D. 
Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261] 
 
 
 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read,  and that I understand and will abide by 
[CONTACT_22138], instructions, and restrictions contained in the attached protocol.  Additionally, I will not initiate this study without approval of the appropriate Institutional Review Board (IRB), and I understand that any changes in the protocol must be approved in 
writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
  
   
Principal Investigator’s Signatur e  Date  
   
   
   
Principal Investigator’s Name (Print)    
     

NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Dat e: April 8, 2013 
 
3 Statistician:  Study Coordinator: N/A  
Zoe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442584] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]   
 ([PHONE_7373]  
Fax: ([PHONE_7374]   
[EMAIL_6809]   
 
Responsible Research Nurse:  N/A  Responsible Data Manager: N/A  
   
NCI-Supplied Agent (s): N/A  
 Other Agent(s ): ALT -803: a “recombinant human superagonist interleukin-15 (IL- 15) complex” 
(AKA, IL -15N72D:IL-15RαSu/IgG1 Fc complex) NSC#: TBD  
   
Investigational Agent  IND#  IND Sponsor  
ALT -803 TBD  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Original/Version 1/April 8, 2013 
 
  
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Dat e: April 8, 2013 
 
4 SCHEMA  
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT-803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.003  mg/kg 
or 
0.006 mg/kg 
or 
0.01 mg/kg 
or 
0.02 mg/kg 
or 
0.03 mg/kg IV D1, W1  
D1, W2  
D1, W3 
D1, W4 42 days  
(4 weeks on, 2 weeks off)  
With up to 4 cycles in the 
absence of unacceptable 
toxicity and disease 
progression 
*Non- steroidal anti-inflammatory medication such as acetaminophen, ibuprofen, Naproxen or 
aspi[INVESTIGATOR_355333]. Not to exceed standard maximum thresholds: 
 
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours Ibuprofen: not to exceed 2400 mg in 24 hours Naproxen: not to exceed 1100 mg in 24 hours Aspi[INVESTIGATOR_248]: not to exceed 3800 mg in 24 hours 
  
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 
Level -1 0.001  mg/kg  (only if the first level is too toxic)  
Level 1  0.003  mg/kg  
Level 2  0.006  mg/kg  
Level 3  0.01 mg/kg  
Level 4  0.02 mg/kg  
Level 5  0.03 mg/kg  
 
 
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Dat e: April 8, [ADDRESS_442585] be 
performed within 30 days before the start of therapy. In the event that the patient’s condition is changing, laboratory evaluations 
should be repeated within 24 hours before initiating the next cycle of therapy. Please refer to the study calendar below for specific timing of required evaluations.  
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  F/U [ADDRESS_442586] 
injection  6 
Month 
F/U 
Visit 
 Within 30 d  Within 14 d  W1 
D1 W2 
D8 W3 
D15 W4 
D22 W5 
D29 W6 
D36 W1 
D1 W2 
D8 W3 
D15 W4 
D22 W5 
D29 W6 
D36   
ALT -803*(A)    X X X X   X X X X     
Informed consent  X                
Demographics  X                
Medical history  X                
Concomitant meds  X  X X X X X X X X X X X X X X 
Physical exam   X X X X X X  X X X X X  X X 
Vital signs   X X X X X X X X X X X X X X X 
Height  X                
Weight  X X X  X  X X X X  X  X X X 
Performance status   X X      X      X X 
CBC w/diff, plts   X X X X X X  X X X X X X X X 
PT/PTT   X               
Serum chemistrya  X X X X X X X X X X X X X X X 
Antinuclear antibody 
(ANA)  X        X       X 
Electrocardiogram (ECG)b   Xb Xb     Xb Xb Xb     Xb   
ECHO (as indicated)  X                
Adverse event evaluation   X X X X X X X X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 8  ± 1 week and 16 ± 2 weeks  X 
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Dat e: April 8, [ADDRESS_442587], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.   
CT or MRI Braind [as 
indicated for symptoms 
only] X If negative at baseline, to be repeated only with symptoms  X 
Radiologic evaluation by 
[CONTACT_393] 1.1  X Radiologic measurements should be performed every 8 ± 1 week and 16 ± 2 weeks  X 
B-HCGe   X              
EBV serostatus  X                
CMV serostatus  X                
Thyroid studies: TSH, T4  X               X 
PK    X      X        
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X  X  X  X    
IFN-γ ELISPOTg   X    X  X    X    
NK-cell functiong   X    X  X    X    
Plasma cytokinesg   X    X  X    X    
Serum Ab to ALT -803g   X      X      X  
PBMC    X    X  X    X   X 
Serum    X    X  X    X    
Abbreviations: Ab , antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natural killer; PET, positron emission 
tomography; PK, pharmacokinetics; PPT, partial thromboplastin time; PT, prothrombin time  
*(A), Agent  
a Blood chem istries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, 
alkaline phosphatase, aspartate transaminae (AST), and alanine transaminase (ALT)  
b ECGs are to be done before ALT -[ADDRESS_442588] ALT -803 injection ( Day1) of all treatment cycles. In addition an ECG is to 
be done at the end of treatment, i.e., end of cycle 1, or after subsequent cycles have been compl eted.  
c baseline tumor assessment scans should be done [ADDRESS_442589] be drawn before the patient 
receives ALT -803 injections on Days 1, 8, 15 and 22 of each treatment cycle.  
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: May 6 , 2013 
 
1 NCI Protocol #:  CITN06 -ALT -803 
 
Local Protocol #: CA-ALT -803-01- 13 
 TITLE:  A Phase 1/2 Study of the Clinical and Immunologic E ffects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with Advanced Melanoma  
 
(Advanced Melanoma – ICD-10053571) 
         Sponsor:  
       
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson 
Cancer Research Center  
 *Principal Investigator:  [INVESTIGATOR_355332], MD  
 University of Washington, Seattle Cancer Care Alliance 
 [ADDRESS_442590] E, G4810 
 Seattle WA [ZIP_CODE] 
 Telephone: 206 -288-7341 
 Fax: 206 -288-6681 
 [EMAIL_6805]  
 Co-Investigators:  Adil Daud , MD 
 University of [LOCATION_004] San Francisco  
 ([PHONE_7370]  
 [EMAIL_6806]
 
  
 Marc Ernstoff, MD  
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7371] 
 [EMAIL_6807]   
  Thomas Waldmann, MD 
 National Cancer Institute  
 ([PHONE_7372] 
 [EMAIL_6808]
 
     
 
  Hing C. Wong, Ph.D.   Altor Bioscience Corporation.  
  Miramar, [LOCATION_012] [ZIP_CODE]   Telephone:  [PHONE_7260] 
  Safety Data Fax:  [PHONE_7261] 
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: May 6 , 2013 
 
2 INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1/2 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Melanoma  
   
Date of Protocol:   
Version # 01  
Version # [ADDRESS_442591]:  
 
Hing C. Wong, Ph.D. 
Altor Bioscience Corporation.  
Miramar, [LOCATION_012] [ZIP_CODE] Telephone:  [PHONE_7260] 
Safety Data Fax:  [PHONE_7261] 
 
 
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol.  
 Additionally, I will not initiate this study without approval of the ap propriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to  subjects.  
  
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
     

NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: May 6 , 2013 
 
3 Statistician:  Study Coordinator: N/A  
Zoe Moodie, PhD   
Fred Hutchinson Cancer Research Center   
[ADDRESS_442592] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]   
 ([PHONE_7373]  
Fax: (206) 667 -4378  
[EMAIL_6809]   
 
Responsible Research Nurse:  N/A  Responsible Data Manager: N/A  
  
 
NCI-Supplied Agent (s): N/A  
 
Other Agent(s ): ALT -803: a “recombinant human superagonist  interleukin -15 (IL -15) complex” 
(AKA, IL -15N72D:IL -15RαSu/IgG1 Fc complex) NSC#: TBD  
   
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Version 2/May 6 , 2013 
 
  
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: May 6 , 2013 
 
4 SCHEMA  
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT-803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.003  mg/kg 
or 
0.006 mg/kg 
or 
0.01 mg/kg 
or 
0.02 mg/kg 
or 
0.03 mg/kg IV D1, W1  
D1, W2 
D1, W3 
D1, W4 42 days  
(4 weeks on, 2 weeks off)  
With up to 4 cycles in the 
absence of unacceptable 
toxicity and disease 
progression 
*Non -steroidal anti- inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thresholds , for example: 
 
Acetaminophen: not to exceed 3000 mg (3 g)  in 24 hours  
Ibuprofen: not to exceed 2400 mg in 24 hours  
Naproxen: not to exceed 1100 mg in 24 hours  
 
 
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 
Level -1 0.001  mg/kg  (only if the first level is too toxic)  
Level 1  0.003  mg/kg  
Level 2  0.006  mg/kg  
Level 3  0.01 mg/kg  
Level 4  0.02 mg/kg  
Level 5  0.03 mg/kg  
 
 
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: May [ADDRESS_442593] be 
performed within 30 days before the start of therapy. In the event that the patient’s condition is changing, laboratory evaluations should be repeated within 24 hours before initiating the next cycle of therapy. Please refer to the study calendar below for specific timing of required evaluations.  
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  F/U [ADDRESS_442594] 
injection  6 
Month 
F/U 
Visit 
 Within 30 d  Within 14 d  W1 
D1 W2 
D8 W3 
D15 W4 
D22 W5 
D29 W6 
D36 W1 
D1 W2 
D8 W3 
D15 W4 
D22 W5 
D29 W6 
D36   
ALT -803*(A)    X X X X   X X X X     
Informed consent  X                
Demographics  X                
Medical history  X                
Concomitant meds  X  X X X X X X X X X X X X X X 
Physical exam#  X X X X X X  X X X X X  X X 
Vital signs  with oxygen 
saturation   X X X X X X X X X X X X X X X 
Height  X                
Weight  X X X  X  X X X X  X  X X X 
Performance status   X X      X      X X 
CBC w/diff, plts   X X X X X X  X X X X X X X X 
PT/PTT   X               
Serum chemistrya  X X X X X X X X X X X X X X X 
Antinuclear antibody 
(ANA)  X        X       X 
Electrocardiogram (ECG)b   Xb Xb     Xb Xb Xb     Xb   
ECHO (as indicated)  X                
Pulmonary function test  
(spi[INVESTIGATOR_038])  X                
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: May 6 , 2013 
 
54 Adverse event evaluation   X X X X X X X X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 8  ± 1 week and 16 ± [ADDRESS_442595], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.   
CT or MRI Braind [as 
indicated for symptoms 
only] X If negative at baseline, to be repeated only with symptoms  X 
Radiologic evaluation by 
[CONTACT_393] 1.1  X Radiologic measurements should be performed every 8 ± 1 week and 16 ± 2 weeks  X 
B-HCGe   X              
EBV serostatus  X                
CMV serostatus  X                
Thyroid studies: TSH, T4  X               X 
PK    X      X        
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X  X  X  X    
IFN-γ ELISPOTg   X    X  X    X    
NK-cell functiong   X    X  X    X    
Plasma cytokinesg   X    X  X    X    
Serum Ab to ALT -803g   X      X      X  
PBMC    X    X  X    X   X 
Serum    X    X  X    X    
Abbreviations: Ab , antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natural killer; PET, positron emission 
tomography; PK, pharmacokinetics; PPT, partial thromboplastin time; PT, prothrombin time  
*(A), Agent  
# Physical exam must always include neurological assessment.  In addition, all patients will have formal ophthalmologic testing prior to starting therapy and 
repeated if clinically indicated . 
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, 
alkaline phosphatase, aspartate transamina se (AST), and alanine transaminase (ALT)  
b ECGs are to be  done before ALT -[ADDRESS_442596] -dose.  ECGs are to be repeated before and at 4 hours (the end of the    
   outpatient obser vation  period) following each subsequent dose.    
c Baseline tumor assessment scans should be done [ADDRESS_442597] be drawn before the patient  
   receives ALT -803 injections on Days 1, 8, 15 and 22 of each treatment cycle.  
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: July 26, 2013 
 
1 NCI Protocol #:  CITN06 -ALT -803 
 
Local Protocol #: CA-ALT -803-01-13 
 TITLE:  A Phase 1/2 Study of the Clinical and Immunologic E ffects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with Advanced Melanoma   
 
(Advanced Melanoma – ICD-10053571) 
         Sponsor:  
       
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson 
Cancer Research Center  
 *Principal Investigator:  [INVESTIGATOR_355332], MD  
 University of Washington, Seattle Cancer Care Alliance  
 [ADDRESS_442598] E, G4810 
 Seattle WA [ZIP_CODE] 
 Telephone: [PHONE_7368] 
 Fax: [PHONE_7369] 
 [EMAIL_6805]  
 Co-Investigators:  Adil Daud , MD 
 University of [LOCATION_004] San Francisco  
 ([PHONE_7370]  
 [EMAIL_6806]
 
  
 Marc Ernstoff, MD  
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7371] 
 [EMAIL_6807]   
  Thomas Waldmann, MD 
 National Cancer Institute  
 ([PHONE_7372] 
 [EMAIL_6808]
 
     
 
  Hing C. Wong, Ph.D.   Altor Bioscience Corporation.   Miramar, [LOCATION_012] [ZIP_CODE]   Telephone: [PHONE_7260]   Safety Data Fax:  [PHONE_7261] 
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: July 26, 2013 
 
2 INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1/2 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Melanoma  
   
Date of Protocol:   
Version # 01  
Version # 02 
Version # [ADDRESS_442599]:  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261] 
 
 
 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol.  Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects. 
  
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
     

NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: July 26, 2013 
 
3 Statistician:  Study Coordinator: N/A  
Zoe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442600] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]   
 ([PHONE_7373]  
Fax: ([PHONE_7374]   
[EMAIL_6809]   
 
Responsible Research Nurse:  N/A  Responsible Data Manager: N/A  
   
NCI-Supplied Agent (s): N/A  
 Other Agent(s ): ALT -803: a “recombinant human superagonist interleukin-15 (IL- 15) complex” 
(AKA, IL -15N72D:IL-15RαSu/IgG1 Fc complex) NSC#: TBD  
   
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Version 3/ July 26, 2013 
 
  
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: July 26, 2013 
 
4 SCHEMA  
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT-803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.001 mg/kg  
or 
0.003 mg/kg 
or 
0.006 mg/kg 
or 
0.01 mg/kg 
or 
0.02 mg/kg 
or 
0.03 mg/kg IV D1, W1  
D1, W2 
D1, W3 
D1, W4 42 days  
(4 weeks on, 2 weeks off)  
With up to 4 cycles in the 
absence of unacceptable 
toxicity and disease 
progression 
*Non- steroidal anti- inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thresholds, for example: 
 
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours Ibuprofen: not to exceed 2400 mg in 24 hours Naproxen: not to exceed 1100 mg in 24 hours 
  
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 
Level -1 0.0005 mg/kg  (only if the first level is too toxic)  
Level 1  0.001 mg/kg   
Level 2  0.003 mg/kg  
Level 3  0.006 mg/kg  
Level 4  0.01 mg/kg  
Level 5  0.02 mg/kg  
Level 6  0.03 mg/kg  
 
 
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: July 26, [ADDRESS_442601] b e 
performed within 30 days before the start of therapy. In the event that the patient’s condition is changing, laboratory evaluations 
should be repeated within 24 hours before initiating the next cycle of therapy. Please refer to the study calendar below f or specific 
timing of required evaluations.  
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  F/U [ADDRESS_442602] 
injection  6 
Month 
F/U 
Visit 
 Within 30 d  Within 14 d  W1 
D1 W2 
D8 W3 
D15 W4 
D22 W5 
D29 W6 
D36 W1 
D1 W2 
D8 W3 
D15 W4 
D22 W5 
D29 W6 
D36   
ALT -803*(A)    X X X X   X X X X     
Informed consent  X                
Demographics  X                
Medical history  X                
Concomitant meds  X  X X X X X X X X X X X X X X 
Physical exam#  X X X X X X  X X X X X  X X 
Vital signs  with oxygen 
saturation   X X X X X X X X X X X X X X X 
Height  X                
Weight  X X X  X  X X X X  X  X X X 
Performance status   X X      X      X X 
CBC w/diff, plts   X X X X X X  X X X X X X X X 
PT/PTT   X               
Serum chemistrya  X X X X X X X X X X X X X X X 
Antinuclear antibody 
(ANA)  X        X       X 
Electrocardiogram (ECG)b   Xb Xb     Xb Xb Xb     Xb   
ECHO (as indicated)  X                
Pulmonary function test 
(spi[INVESTIGATOR_038])  X                
NCI Protocol #:CITN06- ALT -803 CONFIDENTIAL  
Version Date: July 26, 2013 
 
54 Adverse event evaluation   X X X X X X X X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 8  ± 1 week and 16 ± [ADDRESS_442603], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.   
CT or MRI Braind [as 
indicated for symptoms 
only] X If negative at baseline, to be repeated only with symptoms  X 
Radiologic evaluation by 
[CONTACT_393] 1.1  X Radiologic measurements should be performed every 8 ± 1 week and 16 ± 2 weeks  X 
B-HCGe   X              
EBV serostatus  X                
CMV serostatus  X                
Thyroid studies: TSH, T4  X               X 
PK    X      X        
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X  X  X  X    
IFN-γ ELISPOTg   X    X  X    X    
NK-cell functiong   X    X  X    X    
Plasma cytokinesg   X    X  X    X    
Serum Ab to ALT -803g   X      X      X  
PBMC    X    X  X    X   X 
Serum    X    X  X    X    
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natur al killer; PET, positron emission 
tomography; PK, pharmacokinetics; PPT, partial thromboplastin time; PT, prothrombin time  
*(A), A gent 
# Physical exam must always include neurological assessment.  In addition, all patients will have formal ophthalmologic testing  prior to starting therapy and 
repeated if clinically indicated . 
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, 
alkaline phosphatase, aspartate transamina se (AST), and alanine transaminase (ALT)  
b ECGs are to be  done before ALT -[ADDRESS_442604] -dose.  ECGs are to be repeated before and at 4 hours (the end of the    
   outpatient observation period) following each subsequent dose.   
c Baseline tumor assessment scans should be don e [ADDRESS_442605] be drawn before the patient  
   receives ALT -803 injections on Days 1, 8, 15 and 22 of each treatment cycle.  
NCI Protocol #:CITN-06-ALT-803 CONFIDENTIAL 
Version Date: December 02, 2013 
 
1 NC
I Protocol #:  CITN-06 -ALT-803 
 
L
ocal Protocol #: CA-ALT-803-01-13 
 
T
ITLE:  A Phas e 1  Study of the Clinical and Immunologic Effects of ALT-803, a Novel 
Recombinant IL-15 Complex in Patients with Advanced Melanoma   
 
(Advanced Melanoma – ICD-10053571) 
 
 
S
ponsor:  
 
 
 
 
 
 
 
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson 
Cancer Research Center 
 
*Principal Investigator:  [INVESTIGATOR_355332], MD  
 University of Washington, Seattle Cancer Care Alliance 
 [ADDRESS_442606] E, G4810 
 Seattle WA [ZIP_CODE] 
 Telephone: [PHONE_7368] 
 F
ax: [PHONE_7369] 
 kmar
[EMAIL_6810] 
 
Co-Investigators:  Adil Daud, MD 
 Unive
rsity of [LOCATION_004] San Francisco 
 ([PHONE_7370]  
 a
[EMAIL_6811]  
  
 Marc Ernstoff, MD 
 Dartmouth Hitchcock Medical Center 
 ([PHONE_7371] 
 mar
[EMAIL_6812]   
 
 Thomas Waldmann, MD 
 National Cancer Institute 
 ([PHONE_7372] 
 taw
[EMAIL_6813]  
 
The University of Washington and USCF will participate to the dose-escalation phase of the 
trial. Dart
mouth and the NCI will be added in the expansion phase of the trial.  
  
 Hing C. Wong, Ph.D.  
 Altor Bioscience Corporation.  
 Miramar, [LOCATION_012] [ZIP_CODE]  
 Telephone:  [PHONE_7260]  
 Safety Data Fax:  [PHONE_7261]  
NCI Protocol #:CITN-06-ALT-803 CONFIDENTIAL 
Version Date: December 02, 2013 
 
2 INV
ESTIGATOR SIGNATURE [CONTACT_355340]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Melanoma  
   
Date of Protocol:   
Version # 01  
Version # 02  
Version # 03  
Version # [ADDRESS_442607]:  
 
Hing C. Wong, Ph.D.  
Altor Bioscience Corporation.  
Miramar, [LOCATION_012] [ZIP_CODE]  
Telephone:  [PHONE_7260]  
Safety Data Fax:  [PHONE_7261]  
 
 
 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by 
[CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in 
writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, 
except where necessary to eliminate hazards to subjects. 
 
 
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
 
 
  

NCI Protocol #:CITN-06-ALT-803 CONFIDENTIAL 
Version Date: December 02, 2013 
 
3 S
tatistician:   Study Coordinator: N/A  
Z
oe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442608] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]    
 ([PHONE_7373]  
F
ax: ([PHONE_7374]   
[EMAIL_6809]   
 
Responsible Research Nurse: N/A  Responsible Data Manager: N/A  
 
 
 
NCI-Supplied Agent(s): N/A  
 
Other
 Agent(s ): ALT-803: a “recombinant human superagonist interleukin-15 (IL-15) complex” 
(AKA, IL-15N72D: IL-15RαSu/IgG1 Fc complex) NSC#: TBD 
  
 
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Amendment/Version 1.0/November 22, 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NCI Protocol #:CITN-06-ALT-803 CONFIDENTIAL 
Version Date: December 02, 2013 
 
4 C
ANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_355336]:  For patient enrollments:  Submit study data    
CTSU Regulatory Office  
[ADDRESS_442609]  
Philadelphia, PA [ZIP_CODE]  
Phone – 1-866-651-CTSU  
Fax – [PHONE_030]  
Email: 
[EMAIL_6814].o
rg (for submitting regulatory 
documents only)  Please refer to the patient enrollment 
section for instructions on using the 
Oncology Patient Enrollment Network 
(OPEN) at  
https://www.ctsu.org/OPEN_SYSTEM/  
or https://OPEN.ctsu.org . 
 
Contact [CONTACT_56112] -related questions at 
[EMAIL_013].  Data collection for this 
study will be done via 
Medidata Rave (Axio 
Research).   
 
Please see the data 
submission section of the 
protocol for further 
instructions.  
 
 
   
The current version of the study protocol and all supporting documents must be downloa ded from the 
protocol -specific Web page of the CTSU Member Web site located at https://www.ctsu.org .   
For patient eligibility or treatment -related questions:  
Contact [CONTACT_355337] [EMAIL_6815]  or [ADDRESS_442610] the CTSU 
Help Desk by [CONTACT_14223] e -mail:   
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at   https://www.ctsu.org  
 
  
NCI Protocol #:CITN-06-ALT-803 CONFIDENTIAL 
Version Date: December 02, 2013 
 
5 S
CHEMA 
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT -803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.3 μg/kg or 
0.5 μg/kg or 
1 μg/kg or 
3 μg/kg or 
6 μg/kg IV D1, W1  
D1, W2  
D1, W3  
D1, W4  42 days  
(4 weeks on, 2  weeks off)  
With up to 4  cycles in the 
absence of unacceptable 
toxicity and disease 
progression ** 
*Non-steroidal anti-inflammatory medication including agents such as acetaminophen, 
ibuprof
en, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thre
sholds: 
 
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours 
Ibuprofen: not to exceed 2400 mg in 24 hours 
Naproxen: not to exceed 1100 mg in 24 hours 
 
** Additional cycles beyond the 4th cycle may be considered for patients continuing to benefit 
an
d tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
 
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 
Level -1 0.1 μg/kg (only if the first level is too toxic)  
Level 1  0.3 μg/kg 
Level 2  0.5 μg/kg 
Level 3  1 μg/kg 
Level 4  3 μg/kg 
Level 5  6 μg/kg 
 
 
NCI Protocol #:CITN-06-ALT -803 CONFIDENTIAL 
Version Date: December 02, [ADDRESS_442611] be 
performed within 30 days before the start of therapy. In the event that the patient’s condition is changing, laboratory evaluations 
shoul
d be repeated within 24 hours before initiating the next cycle of therapy. Please refer to the study calendar below for specific 
timing of required evaluations. 
 
    F/U 
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442612] inf. 6 
Mo 1 yeari 
 Within 
30 d Within 
14 d W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1 W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1    
ALT -803*(A)    X X X X   X X X X      
Informed consent  X                 
Demographics  X                 
Medical history  X                 
Concomitant meds  X  X X X X X X X X X X X X X X X 
Physical examh  X X X X X X  X X X X X  X X X 
Vital signs  with oxygen 
saturation   X X X X X X X X X X X X X X X X 
Height  X                 
Weight  X X X  X  X X X X  X  X X X X 
Performance status   X X      X      X X X 
CBC w/diff, plts   X X X X X X  X X X X X X X X X 
PT/PTT   X                
Serum chemistrya  X X X X X X X X X X X X X X X X 
Antinuclear antibody 
(ANA)  X        X       X X 
Electrocardiogram (ECG)b   X X X X   X X X X   X X X 
ECHO (as indicated)  X                 
Adverse event evaluation   X X X X X X X X X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 6 ± 1 week and 12 ± [ADDRESS_442613], X Documentation (radiologic) must be provided for patients removed from study for progressive disease.    
NCI Protocol #:CITN-06-ALT -803 CONFIDENTIAL 
Version Date: December 02, 2013 
 
58     F/U 
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442614] or MRI Braind [as 
indicated for symptoms 
only] X If negative at baseline, to be repeated only with symptoms  X  
Radiologic evaluation by 
[CONTACT_393] 1.1  X Radiologic measurements should be performed every 6 ± 1 week and  12 ± 2 weeks  X  
B-HCGe   X               
Thyroid studies: TSH, T4  X               X X 
PKf    X               
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X  X  X  X     
IFN-γ ELISPOTg   X    X  X    X     
NK-cell functiong   X    X  X    X     
Plasma cytokinesg   X    X  X    X     
Serum Ab to ALT -803g   X      X      X   
Other laboratorie sj   X               
Serum         X  X    X     
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natural killer; PET, positron emission 
tomography; PK, pharmacokinetics; PTT, partial thromboplastin time; PT, prothrombin time  
*(A), Agent 
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, alkaline phosphatase, 
aspartate transaminase (AST), and alanine transaminase (ALT)  
b ECGs are to be done before ALT-[ADDRESS_442615] ALT-803 infusion (Cycle 1, Week 1, Day1). As clinically indicated, ECGs are to 
be obtained to evaluate for cardiac toxicity during subsequent doses and cycles of therapy and follow-up visits.  
c Baseline tumor assessment scans should be done [ADDRESS_442616] formal ophthalmologic testing prior to starting therapy and repeated if clinically 
indicated.  
iAdditional cycles beyond the 4th cycle may be considered for patients continuing to benefit and tolerating therapy, upon discussion among the sponsor and Principal 
Investigator. 
jOther labs include: Lactate dehydrogenase, magnesium, phosphate, creatinine kinase and troponin I; must be drawn before and at [ADDRESS_442617] ALT-803 
dose.
NCI Protocol #: CITN -06-ALT -803  
Version Date: October 0 8, 2014 
 
1 
 NCI Protocol #:  CITN -06-ALT -803 
 
Local Protocol #: CA-ALT -803-01-13 
 TITLE:  A Phase 1  Study of the Clinical and Immunologic E ffects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with Advanced Melanoma   
 
(Advanced Melanoma – ICD-10053571) 
  Sponsor:  
      
 
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center  
 
*Principal Investigator:  [INVESTIGATOR_355332], MD 
 Stanford University, Division of Oncology 
 [ADDRESS_442618] CA [ZIP_CODE] 
 [EMAIL_6816]
 
 
Co-Investigators: Adil Daud, MD 
 University of [LOCATION_004] San Francisco  
 ([PHONE_7370] 
 [EMAIL_6806]  
 
 Lionel Lewis, MD  
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7375] 
 [EMAIL_603]  
  
 Sylvia Lee, MD  
 Seattle Cancer Care Alliance 
 ([PHONE_7376] 
 [EMAIL_6817]  
 
 Shernan Holtan,  MD 
 University of Minnesota  
 ([PHONE_7377] 
 [EMAIL_6818]   
  
 Hing C. Wong, Ph.D.  Altor Bioscience Corporation.  Miramar, [LOCATION_012] [ZIP_CODE]  Telephone: [PHONE_7260]  Safety Data Fax:  [PHONE_7261] 
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: October [ADDRESS_442619] L. Kaufman, MD, FACS 
 Rutgers University  
 ([PHONE_7378] 
 [EMAIL_6819]  
  
 Thomas Waldmann, MD 
 National Cancer Institute  
 ([PHONE_7372] 
 [EMAIL_6808]  
 
The SCCA, UCSF , Dartmouth , University of Minnesota, Rutgers University and Stanford 
University  will participate to the dose -escalation phase of the trial. NCI will be added in the 
expansion phase of the trial. 
NCI Protocol #: CITN -06-ALT -803  
Version Date: October 0 8, 2014 
 
3 
 INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Melanoma  
   
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 
Version # [ADDRESS_442620]:  
 
Hing C. Wong, Ph.D. 
Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax:  [PHONE_7261] 
 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read,  and that I understand and will abide by 
[CONTACT_22138], instructions, and restrictions contained in the attached protocol.  Additionally, I will not initiate this study without approval of the appropriate Institutional Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
  
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
    

NCI Protocol #: CITN -06-ALT -803  
Version Date: October 0 8, 2014 
 
4 
 Statistician:  Study Coordinator: N/A  
Zoe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442621] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]   
 ([PHONE_7373]  
Fax: ([PHONE_7374]   
[EMAIL_6809]   
 
Responsible Research Nurse:  N/A  Responsible Data Manager: N/A  
   
NCI-Supplied Agent(s):  N/A  
 Other Agent(s ): ALT -803: a “recombinant human superagonist interleukin-15 (IL-15) complex” 
(AKA, IL -15N72D: IL-15RαSu/IgG1 Fc complex) NSC#: TBD  
   
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Amendment / Version 3.0 /August 2 7, 2014  
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: October 0 8, 2014 
 
5 
 CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_355338]:  For patient enrollments:  Submit study data    
CTSU Regulatory Office  
[ADDRESS_442622] 
Philadelphia, PA [ZIP_CODE] 
Phone – 1-866-651- CTSU  
Fax – [PHONE_030] 
Email: 
[EMAIL_6814].o
rg (for submitting regulatory 
documents only) Please refer to the patient enrollment 
section for instructions on using the 
Oncology Patient Enrollment Network 
(OPEN ) at 
https://w ww.ctsu.org/OPEN_SYSTEM/  
or https://OPEN.ctsu.org . 
 
Contact [CONTACT_56112] -related questions at 
[EMAIL_013].  Data collection for this 
study will be done via  
Medidata Rave (Axio Research) .   
 Please see the data 
submission section of the protocol for further 
instructions.  
 
 
   
The current version of the study protocol and all supporting documents  must be downloaded from the 
protocol- specific Web page of the CTSU Member Web site located at https://www.ctsu.org .   
For patient eligibility or treatment -related questions:  
Contact [CONTACT_355337] [EMAIL_6815]  or [PHONE_7379] 
For questions unrelated to patient eligibility, treatment, or clinical data submission  contact [CONTACT_355339] e- mail:  
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
corresponden ce will be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at   https://www.ctsu.org  
 
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: October 0 8, 2014 
 
6 
 SCHEMA  
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT-803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.3 μg/kg or  
0.5 μ g/kg or  
1 μg/kg or 
3 μg/kg or  
6 μg/kg IV D1, W1  
D1, W2 
D1, W3 
D1, W4 42 days  
(4 weeks on, 2 weeks off)  
With up to 4 cycles in the 
absence of unacceptable 
toxicity and disease 
progression** 
*Non- steroidal anti- inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thresholds:  
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours Ibuprofen: not to exceed 2400 mg in 24 hours Naproxen: not to exceed 1100 mg in 24 hours 
 ** Additional cycles beyond the 4
th cycle may be considered for patients continuing to benefit 
and tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
 
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 
Level -1 0.1 μg/kg (only if the first level is too toxic)  
Level 1  0.3 μg/kg 
Level 2  0.5 μg/kg 
Level 3  1 μg/kg 
Level 4  3 μg/kg 
Level 5  6 μg/kg 
 
 
NCI Protocol #: CITN -06-ALT -803  
Version Date: October [ADDRESS_442623] be performed within 
30 days before the start of therapy. In the event that the patient’s condition is changing, laboratory evaluations should be repeated within 24 hours before initiating the next cycle of therapy. Please refer to the study calenda r below for specific timing of required evaluations. 
    F/U 
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442624] inf. 6 
Mo 1 yeari 
 Within 
30 d Within 
14 d W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1 W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1    
ALT -803*(A)    X X X X   X X X X      
Informed consent  X                 
Demographics  X                 
Medical history  X                 
Concomitant meds  X  X X X X X X X X X X X X X X X 
Physical examh  X X X X X X  X X X X X  X X X 
Vital signs  with oxygen 
saturation   X X X X X X X X X X X X X X X X 
Height  X                 
Weight  X X X  X  X X X X  X  X X X X 
Performance status   X X      X      X X X 
CBC w/diff, plts   X Xk X X X X X X X X X X X X X X 
PT/PTT   X                
Serum chemistrya  X X X X X X X X X X X X X X X X 
Antinuclear antibody 
(ANA)  X        X       X X 
Electrocardiogram (ECG)b   X X X X   X X X X   X X X 
ECHO (as indicated)  X                 
Adverse event evaluation   X X X X X X X X X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 6 ± 1 week and 12  ± [ADDRESS_442625], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.    
CT or MRI Braind [as 
indicated for sympt only]  X If negative at baseline, to be repeated only with symptoms  X  
NCI Protocol #: CITN -06-ALT -803  
Version Date: October 0 8, 2014 
 
60 
     F/U 
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442626] inf. 6 
Mo 1 yeari 
 Within 
30 d Within 
14 d W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1 W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±[ADDRESS_442627] 1.1  X Radiologic measurements should be performed every 6 ± 1 week and  12 ± 2 weeks  X  
B-HCGe   X               
Thyroid studies: TSH, T4  X               X X 
PKf    X               
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X  X  X  X     
IFN-γ ELISPOTg   X    X  X    X     
NK-cell functiong   X    X  X    X     
Plasma cytokinesg   X    X  X    X     
Kyn/Trp ratiog   X    X  X    X     
Serum Ab to ALT -803g   X      X      X   
Other laboratorie sj   X               
Serum         X  X    X     
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natural killer; PET, pos itron emission 
tomo graphy; PK, pharmacokinetics; PT T, partial thromboplastin time; PT, prothrombin time  
*(A):  Agent  
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, alkaline phosphatase, 
aspartate transaminas e (AST), and alanine transaminase (ALT)  
b ECGs are to be done before ALT -[ADDRESS_442628] ALT -803 infusion (Cycle 1, Week 1, Day1) . As clinically indicated, ECGs are to 
be obtained to evaluate for cardiac toxicity during  subsequent dose s and cycles of therapy  and follow -up visits .  
c Baseline tumor assessment scans should be done [ADDRESS_442629] may be done up to 48 hours before ALT -803 administration  
f See pharmacokinetic flow sheet for specific draw times  
g Blood for WB Immunophenotypi[INVESTIGATOR_007], IFN -γ ELISPOT, NK-cell function, plasma cytokines,  Kyn/Trp ratio  and serum Ab to ALT -[ADDRESS_442630] be done  
prior to starting therapy  (Cycle 1, Day 1, Week 1)  and repeated if clinically indicated  (See Section 6.0  for additional details) .  
iAdditional cycles beyond the 4th cycle may be considered for patients continuing to benefit and tolerating therapy, upon discussion among the sponsor and Principal Investigator.  
jOther labs include: Lactate dehydrogenase, magnesium, phosphate, CK and troponin I or T; must be drawn before and at [ADDRESS_442631] ALT -803 dose.  
kCBC w/diff, plts  (Cycle 1, Week 1, Day 1); must be drawn before and at [ADDRESS_442632] ALT -803 dose.  
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: November 20, 2014 
 
1 
 NC
I Protocol #:  CITN-06 -ALT-803 
 
L
ocal Protocol #: CA-ALT-803-01-13 
 
T
ITLE:  A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel 
R
ecombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head and Neck Cancer  
 
 
 
Sponsor:  
 
 
 
 
 
 
 
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson 
Cancer Research Center 
 
*Principal Investigator:  [INVESTIGATOR_355332], MD 
 Stanford University, Division of Oncology 
 [ADDRESS_442633] CA [ZIP_CODE] 
 ([PHONE_7380] 
 kmar
[EMAIL_6820]  
 
Co-Investigators: Lionel Lewis, MD  
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7375] 
 li
[EMAIL_6821]  
  
 Sylvia Lee, MD 
 Seattle Cancer Care Alliance 
 (206) 667 -2218  
 [EMAIL_6817]  
 
 Shernan Holtan, MD 
 University of Minnesota  
 ([PHONE_7377] 
 sg
[EMAIL_6822]  
  
 
 
  
  
 Hing C. Wong, Ph.D.  
 Altor Bioscience Corporation.  
 Miramar, [LOCATION_012] [ZIP_CODE]  
 Telephone:  [PHONE_7260]  
 Safety Data Fax:  [PHONE_7261]  
  
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: November 20, [ADDRESS_442634] L. Kaufman, MD, FACS 
 Rutgers University 
 ([PHONE_7378] 
 How
[EMAIL_6823]  
  
 Marc Ernstoff, MD 
 Cleveland Clinic Foundation 
 ([PHONE_7381] 
 e
[EMAIL_6824]  
  
 Thomas Waldmann, MD 
 National Cancer Institute 
 ([PHONE_7372] 
 taw
[EMAIL_6813]  
 
The SCCA, Cleveland Clinic Foundation , UCSF, Dartmouth, University of Minnesota, Rutgers 
Unive
rsity and Stanford University will participate to the dose-escalation phase of the trial. NCI 
will
 be added in the expansion phase of the trial.  
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: November 20, 2014 
 
3 
 INV
ESTIGATOR SIGNATURE [CONTACT_355340]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Solid Tumors:  Melanoma , Renal 
Cell, Non -Small Cell Lung and Squamous Cell 
Head and Neck Cancer   
   
Date of Protocol:   
Version # 01  
Version # 02  
Version # 03  
Version # 04  
Version # 05  
Version # [ADDRESS_442635]:   
 
Hing C. Wong, Ph.D.  
Altor Bioscience Corporation.  
Miramar, [LOCATION_012] [ZIP_CODE]  
Telephone:  [PHONE_7260]  
Safety Data Fax:  [PHONE_7261]  
 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by 
[CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in 
writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, 
except where necessary to eliminate hazards to subjects. 
 
 
   
Principal Investigator’s Signatur e  Date  
   
   
   
Principal Investigator’s Name (Print)    
 
  

NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: November 20, 2014 
 
4 
 S
tatistician:   Study Coordinator: N/A  
Z
oe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442636] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]    
 ([PHONE_7373]  
F
ax: ([PHONE_7374]   
z
[EMAIL_6825]   
 
Responsible Research Nurse: N/A  Responsible Data Manager: N/A  
  
 
NCI-Supplied Agent(s): N/A  
 
Other
 Agent(s ): ALT-803: a “recombinant human superagonist interleukin-15 (IL-15) complex” 
(AKA, IL-15N72D: IL-15RαSu/IgG1 Fc complex) NSC#: TBD 
  
 
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Amendment / V ersion 4. 0 /October 30, 2014  
  
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: November 20, 2014 
 
5 
 C
ANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_355336]:  For patient enrollments:  Submit study data    
CTSU Regulatory Office  
[ADDRESS_442637]  
Philadelphia, PA [ZIP_CODE]  
Phone – 1-866-651-CTSU  
Fax – [PHONE_030]  
Email: 
[EMAIL_6814].o
rg (for submitting regulatory 
documents only)  Please refer to the patient enrollment 
section for instructions on using the 
Oncology Patient Enrollment Network 
(OPEN ) at 
https://www.ctsu.org/OPEN_SYSTEM/  
or https://OPEN.ctsu.org . 
 
Contact [CONTACT_56112] -related questions at 
[EMAIL_013].  Data collection for this 
study will be done via 
Medidata Rave  (Axio 
Research) .   
 
Please see the data 
submission section of the 
protocol for further 
instructions.  
 
 
   
The current version of the study protocol and all supporting documents  must be downloaded from the 
protocol -specific Web page of t he CTSU Member Web site located at https://www.ctsu.org .   
For patient eligibility or treatment -related questions:  
Contact [CONTACT_355337] [EMAIL_6815]  or [ADDRESS_442638] the 
CTSU Help Desk by [CONTACT_14223] e -mail:   
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at   https://www.ctsu.org  
 
  
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: November 20, 2014 
 
6 
 S
CHEMA 
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT -803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.3 μg/kg or  
0.5 μg/kg or  
1 μg/kg or 
3 μg/kg or  
6 μg/kg IV D1, W1  
D1, W2  
D1, W3  
D1, W4  42 days  
(4 weeks on, 2  weeks off)  
With up to 4  cycles in the 
absence of unacceptable 
toxicity and disease 
progression ** 
*Non-steroidal anti-inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thre
sholds: 
 
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours 
Ibuprofen: not to exceed 2400 mg in 24 hours 
Naproxen: not to exceed 1100 mg in 24 hours 
 
** Additional cycles beyond the 4th cycle may be considered for patients continuing to benefit 
a
nd tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
 
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 
Level -1 0.1 μg/kg (only if the first level is too toxic)  
Level 1  0.3 μg/kg 
Level 2  0.5 μg/kg 
Level 3  1 μg/kg 
Level 4  3 μg/kg 
Level 5  6 μg/kg 
 
 
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: November 20, [ADDRESS_442639] be performed within 
30 days before the start of therapy. In the event that the patient’s condition is changing, laboratory evaluations should be repeated within 24 hours 
before initiating the next cycle of therapy. Please refer to the study calendar below for specific timing of required evaluations. 
    F/U 
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442640] inf. 6 
Mo 1 yeari 
 Within 
30 d Within 
14 d W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1 W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1    
ALT -803*(A)    X X X X   X X X X      
Informed consent  X                 
Demographics  X                 
Medical history  X                 
Concomitant meds  X  X X X X X X X X X X X X X X X 
Physical examh  X X X X X X  X X X X X  X X X 
Vital signs  with oxygen 
saturation   X X X X X X X X X X X X X X X X 
Height  X                 
Weight  X X X  X  X X X X  X  X X X X 
Performance status   X X      X      X X X 
CBC w/diff, plts   X Xk X X X X X X X X X X X X X X 
PT/PTT   X                
Serum chemistrya  X X X X X X X X X X X X X X X X 
Antinuclear antibody 
(ANA)  X        X       X X 
Electrocardiogram (ECG)b   X X X X   X X X X   X X X 
ECHO (as indicated)  X                 
Adverse event evaluation   X X X X X X X X X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 6 ± 1 week and 12  ± [ADDRESS_442641], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.    
CT or MRI Braind [as 
indicated for sympt only]  X If negative at baseline, to be repeated only with symptoms  X  
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: November 20, 2014 
 
60 
     F/U 
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442642] inf. 6 
Mo 1 yeari 
 Within 
30 d Within 
14 d W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1 W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±[ADDRESS_442643] 1.1  X Radiologic measurements should be performed every 6 ± 1 week and  12 ± 2 weeks  X  
B-HCGe   X               
Thyroid studies: TSH, T4  X               X X 
PKf    X               
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X  X  X  X     
IFN-γ ELISPOTg   X    X  X    X     
NK-cell functiong   X    X  X    X     
Plasma cytokinesg   X    X  X    X     
Kyn/Trp ratiog   X    X  X    X     
Serum Ab to ALT -803g   X      X      X   
Other laboratorie sj   X               
Serum         X  X    X     
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natural killer; PET, positron emission 
tomography; PK, pharmacokinetics; PTT, partial thromboplastin time; PT, prothrombin time  
*(A): Agent 
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, alkaline phosphatase, 
aspartate transaminase (AST), and alanine transaminase (ALT)  
b ECGs are to be done before ALT-[ADDRESS_442644] ALT-803 infusion (Cycle 1, Week 1, Day1). As clinically indicated, ECGs are to 
be obtained to evaluate for cardiac toxicity during subsequent doses and cycles of therapy and follow-up visits.  
c Baseline tumor assessment scans should be done [ADDRESS_442645] may be done up to 48 hours before ALT-803 administration  
f See pharmacokinetic flow sheet for specific draw times 
g Blood for WB Immunophenotypi[INVESTIGATOR_007], IFN-γ ELISPOT, NK-cell function, plasma cytokines, Kyn/Trp ratio and serum Ab to ALT-[ADDRESS_442646] be done 
prior to starting therapy (Cycle 1, Day 1, Week 1) and repeated if clinically indicated (See Section 6.0  for additional details) .  
iAdditional cycles beyond the 4th cycle may be considered for patients continuing to benefit and tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
jOther labs include: Lactate dehydrogenase, magnesium, phosphate, CK and troponin I or T ; must be drawn before  and at [ADDRESS_442647] ALT-803 dose. 
kCBC w/diff, plts (Cycle 1, Week 1, Day 1); must be drawn before  and at [ADDRESS_442648] ALT-803 dose.  
NCI Protocol #: CITN -06-ALT -803  
Version Date: January 26 , 2015 
 
1 
 NCI Protocol #:  CITN -06-ALT -803 
 
Local Protocol #: CA-ALT -803-01-13 
 TITLE:  A Phase 1  Study of the Clinical and Immunologic E ffects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head and Neck Cancer  
 
 
 Sponsor:  
      
 
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center  
 *Principal Investigator:  [INVESTIGATOR_355332], MD  
 Stanford University, Division of Oncology 
 [ADDRESS_442649] CA [ZIP_CODE] 
 ([PHONE_7380] 
 [EMAIL_6816]
 
 Co-Investigators: Lionel Lewis, MD 
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7375] 
 [EMAIL_603]
 
  
 Sylvia Lee, MD  
 Seattle Cancer Care Alliance  
 ([PHONE_7376] 
 [EMAIL_6817]  
  Shernan Holtan, MD 
 University of Minnesota 
 ([PHONE_7377] 
 [EMAIL_6818]
 
  
    
 
 Hing C. Wong, Ph.D.  Altor Bioscience Corporation.  Miramar, [LOCATION_012] [ZIP_CODE]  Telephone: [PHONE_7260]  Safety Data Fax:  [PHONE_7261] 
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: January [ADDRESS_442650] L. Kaufman, MD, FACS 
 Rutgers University  
 ([PHONE_7378] 
 [EMAIL_6819]  
  
 Marc Ernstoff, MD  
 Cleveland Clinic Foundation 
 ([PHONE_7381] 
 [EMAIL_615]  
  
 Thomas Waldmann, MD 
 National Cancer Institute  
 ([PHONE_7372] 
 [EMAIL_6808]  
 
The SCCA , Cleveland Clinic Foundation, UCSF , Dartmouth, University of Minnesota, Rutgers 
University and Stanford University  will participate to the dose -escalation phase of the trial. NCI 
will be added in the expansion phase of the trial.  
NCI Protocol #: CITN -06-ALT -803  
Version Date: January 26 , 2015 
 
3 
 INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Solid Tumors: Melanoma, Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head 
and Neck Cancer   
   
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 Version # 05  
Version # 06 
Version # [ADDRESS_442651]:   
 
Hing C. Wong, Ph.D. 
Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] Safety Data Fax:  [PHONE_7261] 
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol.  Additionally, I will not initiate this study without approval of the appropriate Institutional Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
  
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
   

NCI Protocol #: CITN -06-ALT -803  
Version Date: January 26 , 2015 
 
4 
 Statistician:  Study  Coordinator: N/A  
Zoe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442652] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]   
 ([PHONE_7373]  
Fax: ([PHONE_7374]   
[EMAIL_6809]   
 
Responsible Research Nurse:  N/A  Responsible Data Manager: N/A  
   
NCI-Supplied Agent(s):  N/A  
 Other Agent(s ): ALT -803: a “recombinant human superagonist interleukin-15 (IL-15) complex” 
(AKA, IL -15N72D: IL-15RαSu/IgG1 Fc complex) NSC#: TBD  
   
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Amendment / Version 5.0 /January 21, 2015  
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: January 26 , 2015 
 
5 
 CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_293843]:  For patient enrollments:  Submit study data    
CTSU Regulatory Office  
[ADDRESS_442653] 
Philadelphia, PA [ZIP_CODE] 
Phone – 1-866-651- CTSU  
Fax – [PHONE_030] 
Email: 
[EMAIL_6814].o
rg (for submitting regulator y 
documents only) Please refer to the patient enrollment 
section for instructions on using the 
Oncology Patient Enrollment Network 
(OPEN ) at 
https://www.ctsu.org/OPEN_SYSTEM/  
or https://OPEN.ctsu.org . 
 
Contact [CONTACT_56112] -related questions at 
[EMAIL_013].  Data collection for this 
study will be done via  
Medidata Rave (Axio Research) .   
 Please see the data 
submission section of the protocol for further 
instructions.  
 
 
   
The current version of the study protocol and all supporting documents  must be downloaded from the 
protocol- specific Web page of the CTSU Member Web site located at https://www.ctsu.org .   
For patient eligibility or treatment -related questions:  
Contact [CONTACT_355337] [EMAIL_6815]  or [PHONE_7379] 
For questions unrelated to patient eligibility, treatment, or clinical data submission  contact [CONTACT_355339] e- mail:  
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at   https://www.ctsu.org  
 
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: January 26 , 2015 
 
6 
 SCHEMA  
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT-803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.3 μg/kg or  
0.5 μ g/kg or  
1 μg/kg or 
3 μg/kg or  
6 μg/kg IV D1, W1  
D1, W2 
D1, W3 
D1, W4 42 days 
(4 weeks on, 2 weeks off)  
With up to 4 cycles in the 
absence of unacceptable 
toxicity and disease 
progression** 
*Non- steroidal anti- inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thresholds:  
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours Ibuprofen: not to exceed 2400 mg in 24 hours Naproxen: not to exceed 1100 mg in 24 hours 
 ** Additional cycles beyond the 4
th cycle may be considered for patients continuing to benefit 
and tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
 
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 
Level -1 0.1 μg/kg (only if the first level is too toxic)  
Level 1  0.3 μg/kg 
Level 2  0.5 μg/kg 
Level 3  1 μg/kg 
Level 4  3 μg/kg 
Level 5  6 μg/kg 
 
 
NCI Protocol #: CITN -06-ALT -803  
Version Date: January [ADDRESS_442654] be performed within 
30 days before the start of therapy. In the event that the patient’s condition is changing, laboratory evaluations should be repeated within 24 hours before initiating the next cycle of therapy. Please refer to the study calenda r below for specific timing of required evaluations. 
    F/U 
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442655] inf. 6 
Mo 1 yeari 
 Within 
30 d Within 
14 d W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1 W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1    
ALT -803*(A)    X X X X   X X X X      
Informed consent  X                 
Demographics  X                 
Medical history  X                 
Concomitant meds  X  X X X X X X X X X X X X X X X 
Physical examh  X X X X X X  X X X X X  X X X 
Vital signs  with oxygen 
saturation   X X X X X X X X X X X X X X X X 
Height  X                 
Weight  X X X  X  X X X X  X  X X X X 
Performance status   X X      X      X X X 
CBC w/diff, plts   X Xk X X X X X X X X X X X X X X 
PT/PTT   X                
Serum chemistrya  X X X X X X X X X X X X X X X X 
Antinuclear antibody 
(ANA)  X        X       X X 
Electrocardiogram (ECG)b   X X X X   X X X X   X X X 
ECHO (as indicated)  X                 
Adverse event evaluation   X X X X X X X X X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 6 ± 1 week and 12  ± [ADDRESS_442656], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.    
CT or MRI Braind [as 
indicated for sympt only]  X If negative at baseline, to be repeated only with symptoms  X  
NCI Protocol #: CITN -06-ALT -803  
Version Date: January 26 , 2015 
 
60 
     F/U 
  
Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442657] inf. 6 
Mo 1 yeari 
 Within 
30 d Within 
14 d W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±1 W1 
D1±1 W2 
D8±1 W3 
D15±1 W4 
D22±1 W5 
D29±1 W6 
D36±[ADDRESS_442658] 1.1  X Radiologic measurements should be performed every 6 ± 1 week and  12 ± 2 weeks  X  
B-HCGe   X               
Thyroid studies: TSH, T4  X               X X 
PKf    X               
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X  X  X  X     
IFN-γ ELISPOTg   X    X  X    X     
NK-cell functiong   X    X  X    X     
Plasma cytokinesg   X    X  X    X     
Kyn/Trp ratiog   X    X  X    X     
Serum Ab to ALT -803g   X      X      X   
Other laboratorie sj   X               
Serum         X  X    X     
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natural killer; PET, pos itron emission 
tomo graphy; PK, pharmacokinetics; PT T, partial thromboplastin time; PT, prothrombin time  
*(A):  Agent  
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, alkaline phosphatase, 
aspartate transaminas e (AST), and alanine transaminase (ALT)  
b ECGs are to be done before ALT -[ADDRESS_442659] ALT -803 infusion (Cycle 1, Week 1, Day1) . As clinically indicated, ECGs are to 
be obtained to evaluate for cardiac toxicity during  subsequent dose s and cycles of therapy  and follow -up visits .  
c Baseline tumor assessment scans should be done [ADDRESS_442660] may be done up to 48 hours before ALT -803 administration  
f See pharmacokinetic flow sheet for specific draw times  
g Blood for WB Immunophenotypi[INVESTIGATOR_007], IFN -γ ELISPOT, NK-cell function, plasma cytokin es, Kyn/Trp ratio  and serum Ab to ALT -[ADDRESS_442661] be done  
prior to starting therapy  (Cycle 1, Day 1, Week 1)  and repeated if clinically indicated  (See Section 6.0  for additional details) .  
iAdditional cycles beyond the 4th cycle may be considered for patients continuing to benefit and tolerating therapy, upon discussion among the sponsor and Principal Investigator.  
jOther labs include: Lactate dehydrogenase, magnesium, phosphate, CK and troponin I  or T; must be drawn before and at [ADDRESS_442662] ALT -803 dose.  
kCBC w/diff, plts (Cycle 1, Week 1, Day 1); must be drawn before and at [ADDRESS_442663] ALT -803 dose.  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: June 11, 2015  
 
1 
 NC
I Protocol #:  CITN-06 -ALT-803 
 
L
ocal Protocol #: CA-ALT-803-01-13 
 
T
ITLE:  A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel 
R
ecombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head and Neck Cancer 
 
 
 
Sponsor:  
 
 
 
 
 
 
 
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson 
Cancer Research Center 
 
*Principal Investigator:  [INVESTIGATOR_355335], MD 
 C
leveland Clinic Foundation 
 [ADDRESS_442664] 
 C
leveland, OH [ZIP_CODE] 
 ([PHONE_7381] 
 e
[EMAIL_6824]  
 
Co-Investigators: Lionel Lewis, MD 
 Dartmouth Hitchcock Medical Center 
 (603) 650 -8685 
 [EMAIL_603]  
  
 Sylvia Lee, MD 
 Seattle Cancer Care Alliance 
 (206) 667 -2218 
 [EMAIL_6817]  
 
 Shernan Holtan, MD 
 University of Minnesota 
 (612) 301 -1095 
 [EMAIL_6818]  
  
 
 
  
  
 Hing C. Wong, Ph.D.  
 Altor Bioscience Corporation.  
 Miramar, [LOCATION_012] [ZIP_CODE]  
 Telephone:  [PHONE_7260]  
 Safety Data Fax:  [PHONE_7261]  
  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: June 11, [ADDRESS_442665] L. Kaufman, MD, FACS 
 Rutgers University 
 ([PHONE_7378] 
 How
[EMAIL_6823]  
  
 Vamsidhar Velcheti, MD 
 Cleveland Clinic Foundation 
 ([PHONE_7382] 
 v
[EMAIL_6826]  
  
 Thomas Waldmann, MD 
 National Cancer Institute 
 ([PHONE_7372] 
 taw
[EMAIL_6813]  
 
The SCCA, Cleveland Clinic Foundation, UCSF , Uni versity of Minnesota and Rutgers 
Uni
versity will participate to the dose-escalation phase of the trial. NCI will be added in the 
e
xpansion phase of the trial. 
NCI Protocol #: CITN- 06-ALT-803  
Version Date: June 11, 2015  
 
3 
 INV
ESTIGATOR SIGNATURE [CONTACT_355340]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Solid Tumors: Melanoma , Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head 
and Neck Cancer   
   
Date of Protocol:   
Version # 01  
Version # 02  
Version # 03  
Version # 04  
Version # 05  
Version # 06  
Version # 07  
Version #[ADDRESS_442666]:   
 
Hing C. Wong, Ph.D.  
Altor Bioscience Corporation.  
Miramar, [LOCATION_012] [ZIP_CODE]  
Telephone:  [PHONE_7260]  
Safety Data Fax:  [PHONE_7261]  
 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by 
[CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in 
writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, 
except where necessary to eliminate hazards to subjects. 
 
 
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
  

NCI Protocol #: CITN- 06-ALT-803  
Version Date: June 11, 2015  
 
4 
 S
tatistician:   Study Coordinator: N/A  
Z
oe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442667] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]    
 ([PHONE_7373]  
F
ax: ([PHONE_7374]   
[EMAIL_6809]   
 
Responsible Research Nurse: N/A  Responsible Data Manager: N/A  
 
 
 
NCI-Supplied Agent(s): N/A  
 
Other
 Agent(s ): ALT-803: a “recombinant human superagonist interleukin-15 (IL-15) complex” 
(AKA, IL-15N72D: IL-15RαSu/IgG1 Fc complex) NSC#: TBD 
  
 
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Amendment / Version 6.0 /J une 3, 2015  
  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: June 11, 2015  
 
5 
 C
ANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_355336]:  For patient enrollments:  Submit study data    
CTSU Regulatory Office  
[ADDRESS_442668]  
Philadelphia, PA [ZIP_CODE]  
Phone – 1-866-651-CTSU  
Fax – [PHONE_030]  
Email: 
[EMAIL_6814].o
rg (for submitting regulatory 
documents only)  Please refer to the patient enrollment 
section for instructions on using the 
Oncology Patient Enrollment Network 
(OPEN ) at 
https://www.ctsu.org/OPEN_SYSTEM/  
or https://OPEN.ctsu.org . 
 
Contact [CONTACT_56112] -related questions at 
[EMAIL_013].  Data collection for this 
study will be done via 
Medidata Rave  (Axio 
Research) .   
 
Please see the data 
submission section of the 
protocol for further 
instructions.  
 
 
   
The current version of the study protocol and all supporting documents  must be downloaded from the 
protocol -specific Web page of the CTSU Member Web site located at https://www.ctsu.org .   
For patient eligibility or treatment -related questions:  
Contact [CONTACT_355337] [EMAIL_6815]  or [ADDRESS_442669] the 
CTSU Help Desk by [CONTACT_14223] e -mail:   
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
corresponden ce will be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at   https://www.ctsu.org  
 
  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: June 11, 2015  
 
6 
 S
CHEMA 
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT -803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.3 μg/kg or  
0.5 μg/kg or  
1 μg/kg or 
3 μg/kg or  
6 μg/kg IV D1, W1  
D1, W2  
D1, W3  
D1, W4  42 days  
(4 weeks on, 2  weeks off)  
With up to 4  cycles in the 
absence of unacceptable 
toxicity and disease 
progression ** 
*Non-steroidal anti-inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thre
sholds: 
 
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours 
Ibuprofen: not to exceed 2400 mg in 24 hours 
Naproxen: not to exceed 1100 mg in 24 hours 
 
** Additional cycles beyond the 4th cycle may be considered for patients continuing to benefit 
a
nd tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
 
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 
Level -1 0.1 μg/kg (only if the first level is too toxic)  
Level 1  0.3 μg/kg 
Level 2  0.5 μg/kg 
Level 3  1 μg/kg 
Level 4  3 μg/kg 
Level 5  6 μg/kg 
 
 
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: June 11, [ADDRESS_442670] be performed within 30 days before the start of 
therapy. In the event that the patient’s condition is changing, laboratory evaluations should be repeated within 24 hours before initiating the next cycle of 
therapy. Please refer to the study calendar below for specific timing of required evaluations. 
    F/U 
  Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442671] 
infusion  6 
Mo 1  
yeari 
 Within 
30 days Within 
14 days Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1  Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1     D1±1  D4±1 D1±1  D4±1 
ALT -803*(A)    X  X X X   X  X X X      
Informed consent  X                   
Demographics  X                   
Medical history  X                   
Concomitant meds  X  X  X X X X X X  X X X X X X X X 
Physical examh  X X  X X X X  X  X X X X  X X X 
Vital signs with oxygen 
saturation   X X  X X X X X X  X X X X X X X X 
Height  X                   
Weight  X X X   X  X X X  X  X  X X X X 
Performance status   X X       X       X X X 
CBC w/diff, plts   X Xk X X X X X X X X X X X X X X X X 
PT/PTT   X                  
Serum chemistrya  X X  X X X X X X  X X X X X X X X 
Antinuclear antibody (ANA)  X         X        X X 
Electrocardiogram (ECG)b   X  X X X   X  X X X   X X X 
ECHO (as indicated)  X                   
Adverse event evaluation   X X  X X X X X X  X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 6 ± 1 week and 12 ± [ADDRESS_442672], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.    
CT or MRI Braind [as 
indicated for sympt only]  X If negative at baseline, to be repeated only with symptoms  X  
Radiologic evaluation by 
[CONTACT_393] 1.1  X Radiologic measurements should be performed every 6 ± 1 week and  12 ± 2 weeks  X  
NCI Protocol #: CITN- 06-ALT-803  
Ve
rsion Date: June 11, 2015 
 
62 
     F/U 
  Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442673] 
infusion  6 
Mo 1  
yeari 
 Within 
30 days Within 
14 days Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1  Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1     D1±1  D4±1 D1±1  D4±1 
B-HCGe   X                 
Thyroid studies: TSH, T4  X                 X X 
PKf    X                 
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X X  X X    X     
IFN-γ ELISPOTg   X     X  X          
NK-cell functiong   X X X   X  X X         
Plasma cytokinesg   X     X  X     X     
Kyn/Trp ratiog   X     X  X     X     
Serum Ab to ALT -803g   X       X       X   
Other laboratoriesj   X                 
Serum Storage (optional)    X     X            
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natural killer; PET, positron emission to mography; PK, 
pharmacokinetics; PTT, partial thromboplastin time; PT, prothrombin time  
*(A): Agent 
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, alkaline phosphatase, aspartate 
transaminase (AST), and alanine transaminase (ALT)  
b ECG
s are to be done before ALT-[ADDRESS_442674] ALT-803 infusion (Cycle 1, Week 1, Day1). As clinically indicated, ECGs are to be obtained to 
evaluate for cardiac toxicity during subsequent doses and cycles of therapy and follow-up visits.  
c Baseline tumor assessment scans should be done [ADDRESS_442675] may be done up to 48 hours before ALT-803 administration  
f See pharmacokinetic flow sheet for specific draw times 
g Blood for WB Immunophenotypi[INVESTIGATOR_007], IFN-γ ELISPOT, NK-cell function, plasma cytokines, Kyn/Trp ratio and serum Ab to ALT-[ADDRESS_442676] be done prior to starting 
therapy (Cycle 1, Day 1, Week 1) and repeated if clinically indicated (See Section 6.0  for additional details) .  
iAdditional cycles beyond the 4th cycle may be considered for patients continuing to benefit and tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
jOther labs include: Lactate dehydrogenase, magnesium, phosphate, CK and troponin I or T ; must be drawn before  and at [ADDRESS_442677] ALT-803 dose. 
kCBC w/diff, plts (Cycle 1, Week 1, Day 1); must be drawn before  and at [ADDRESS_442678] ALT-803 dose.  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: August 5, 2015 
 
1 
 NC
I Protocol #:  CITN-06 -ALT-803 
 
L
ocal Protocol #: CA-ALT-803-01-13 
 
T
ITLE:  A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel 
R
ecombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head and Neck Cancer 
 
 
 
Sponsor:  
 
 
 
 
 
 
 
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson 
Cancer Research Center 
 
*Principal Investigator:  [INVESTIGATOR_355335], MD 
 Cleveland Clinic Foundation 
 [ADDRESS_442679] 
 C
leveland, OH [ZIP_CODE] 
 ([PHONE_7381] 
 [EMAIL_615]   
 
Co-Investigators: Lionel Lewis, MD  
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7375] 
 [EMAIL_603]  
  
 Sylvia Lee, MD 
 Seattle Cancer Care Alliance 
 (206) 667 -2218  
 [EMAIL_6817]  
 
 Shernan Holtan, MD 
 University of Minnesota  
 ([PHONE_7377] 
 [EMAIL_6818]  
  
 
 
  
  
 Hing C. Wong, Ph.D.  
 Altor Bioscience Corporation.  
 Miramar, [LOCATION_012] [ZIP_CODE]  
 Telephone:  [PHONE_7260]  
 Safety Data Fax:  [PHONE_7261]  
  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: August 5, [ADDRESS_442680] L. Kaufman, MD, FACS 
 Rutgers University 
 ([PHONE_7378] 
 [EMAIL_6819]  
  
 Vamsidhar Velcheti, MD 
 Cleveland Clinic Foundation 
 ([PHONE_7382] 
 [EMAIL_6827]  
  
 Thomas Waldmann, MD 
 National Cancer Institute 
 ([PHONE_7372] 
 [EMAIL_6808]  
 
The SCCA, Cleveland Clinic Foundation, UCSF, University of Minnesota and Rutgers 
Unive
rsity will participate to the dose-escalation phase of the trial. NCI will be added in the 
e
xpansion phase of the trial. 
NCI Protocol #: CITN- 06-ALT-803  
Version Date: August 5, 2015 
 
3 
 INV
ESTIGATOR SIGNATURE [CONTACT_355340]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Solid Tumors: Melanoma , Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head 
and Neck Cancer   
   
Date of Protocol:   
Version # 01  
Version # 02  
Version # 03  
Version # 04  
Version # 05  
Version # 06  
Version # 07  
Version #  08 
Version #  [ADDRESS_442681]:   
 
Hing C. Wong, Ph.D.  
Altor Bioscience Corporation.  
Miramar, [LOCATION_012] [ZIP_CODE]  
Telephone:  [PHONE_7260]  
Safety Data Fax:  [PHONE_7261]  
 
By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by 
[CONTACT_22138], instructions, and restrictions contained in the attached protocol. 
 
Additionally, I will not initiate this study without approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in 
writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, 
except where necessary to eliminate hazards to subjects. 
 
 
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
  

NCI Protocol #: CITN- 06-ALT-803  
Version Date: August 5, 2015 
 
4 
 S
tatistician:   Study Coordinator: N/A  
Z
oe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442682] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]    
 ([PHONE_7373]  
F
ax: ([PHONE_7374]   
z
[EMAIL_6825]   
 
Responsible Research Nurse: N/A  Responsible Data Manager: N/A  
  
 
NCI-Supplied Agent(s): N/A  
 
Other
 Agent(s ): ALT-803: a “recombinant human superagonist interleukin-15 (IL-15) complex” 
(AKA, IL-15N72D: IL-15RαSu/IgG1 Fc complex) NSC#: TBD 
  
 
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Amendment / V ersion 7 .0 /July 28, 2015  
  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: August 5, 2015 
 
5 
 C
ANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_355336]:  For patient enrollments:  Submit study data    
CTSU Regulatory Office  
[ADDRESS_442683]  
Philadelphia, PA [ZIP_CODE]  
Phone – 1-866-651-CTSU  
Fax – [PHONE_030]  
Email: 
[EMAIL_6814].o
rg (for submitting regulatory 
documents only)  Please refer to the patient enrollment 
section for instructions on using the 
Oncology Patient Enrollment Network 
(OPEN ) at 
https://www.ctsu.org/OPEN_SYSTEM/  
or https://OPEN.ctsu.org . 
 
Contact [CONTACT_56112] -related questions at 
[EMAIL_013].  Data collection for this 
study will be done via 
Medidata Rave  (Axio 
Research) .   
 
Please see the data 
submission section of the 
protocol for further 
instructions.  
 
 
   
The current version of the study protocol and all supporting documents  must be downloaded from the 
protocol -specific Web page of the CTSU Member Web site located at https://www.ctsu.org .   
For patient eligibility or treatment -related questions:  
Contact [CONTACT_355337] [EMAIL_6815]  or [ADDRESS_442684] the 
CTSU Help Desk by [CONTACT_14223] e -mail:   
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at   https://www.ctsu.org  
 
  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: August 5, 2015 
 
6 
 S
CHEMA 
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT -803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.3 μg/kg or  
0.5 μg/kg or  
1 μg/kg or  
3 μg/kg or  
6 μg/kg  IV D1, W1  
D1, W2  
D1, W3  
D1, W4  42 days  
(4 weeks on, 2  weeks off)  
With up to 4  cycles in the 
absence of unacceptable 
toxicity and disease 
progression**  6 μg/kg  
10 μg/kg  
15 μg/kg  
20 μg/kg   SQ 
*Non-steroidal anti-inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thre
sholds: 
 
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours 
Ibuprofen: not to exceed 2400 mg in 24 hours 
Naproxen: not to exceed 1100 mg in 24 hours 
 
** Additional cycles beyond the 4th cycle may be considered for patients continuing to benefit 
a
nd tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
 
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 Route of Administration  
Level -1 0.1 μg/kg (only if the  first level is too toxic)  IV 
Level 1  0.3 μg/kg  IV 
Level 2  0.5 μg/kg  IV 
Level 3  1 μg/kg  IV 
Level 4  3 μg/kg  IV 
Level 5  6 μg/kg  IV 
Level 5a1 6 μg/kg  SQ 
Level 6  10 μg/kg  SQ 
Level 7  15 μg/kg  SQ 
Level 82 20 μg/kg  SQ 
1With protocol version #9, ALT-803 dosing is changed from IV to SQ, and dose level 5 is repeated to confirm 
safety with the new route of administration. 
2The dose of ALT-803 will be increased in increments of 5 μg/kg if a minimum of three patients have been 
treated at dose level 8 (20 μg/kg), and the Maximum Tolerated Dose (MTD) and Optimum Biological Dose 
(OBD) have not been identified. Enrollment will continue until the MTD/OBD is identified.  
 
NCI Protocol #: CITN- 06-ALT-803  
Version Date: August 5, [ADDRESS_442685] be performed within 30 days before the start of 
therapy. In the event that the patient’s condition is changing, laboratory evaluations should be repeated within 24 hours before initiating the next cycle of 
therapy. Please refer to the study calendar below for specific timing of required evaluations. 
    F/U 
  Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442686] 
dose 6 
Mo 1  
yeari 
 Within 
30 days Within 
14 days Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1  Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1     D1±1  D4±1 D1±1  D4±1 
ALT -803*(A)    X  X X X   X  X X X      
Informed consent  X                   
Demographics  X                   
Medical history  X                   
Concomitant meds  X  X  X X X X X X  X X X X X X X X 
Physical examh  X X  X X X X  X  X X X X  X X X 
Vital signs with oxygen 
saturation   X X  X X X X X X  X X X X X X X X 
Height  X                   
Weight  X X X   X  X X X  X  X  X X X X 
Performance status   X X       X       X X X 
CBC w/diff, plts   X Xk X X X X X X X X X X X X X X X X 
PT/PTT   X                  
Serum chemistrya  X X  X X X X X X  X X X X X X X X 
Antinuclear antibody (ANA)  X         X        X X 
Electrocardiogram (ECG)b   X  X X X   X  X X X   X X X 
ECHO (as indicated)  X                   
Adverse event evaluation   X X  X X X X X X  X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 6 ± 1 week and 12 ± [ADDRESS_442687], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.    
CT or MRI Braind [as 
indicated for sympt only]  X If negative at baseline, to be repeated only with symptoms  X  
Radiologic evaluation by 
[CONTACT_393] 1.1  X Radiologic measurements should be performed every 6 ± 1 week and  12 ± 2 weeks  X  
NCI Protocol #: CITN- 06-ALT-803  
Version Date: August 5, 2015 
 
63 
     F/U 
  Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442688] 
dose 6 
Mo 1  
yeari 
 Within 
30 days Within 
14 days Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1  Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1     D1±1  D4±1 D1±1  D4±1 
Injection Site Evaluation     X X X X   X X X X X   X   
B-HCGe   X                 
Thyroid studies: TSH, T4  X                 X X 
PKf    X                 
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X X  X X    X     
IFN-γ ELISPOTg   X     X  X          
NK-cell functiong   X X X   X  X X         
Plasma cytokinesg   X     X  X     X     
Kyn/Trp ratiog   X     X  X     X     
Serum Ab to ALT -803g   X       X       X   
Other laboratoriesj   X                 
Serum Storage (optional)    X     X            
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natural killer; PET, positron emission tomography; PK, 
pharmacokinetics; PTT, partial thromboplastin time; PT, prothrombin time  
*(A): Agent 
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, alkaline phosphatase, aspartate 
transaminase (AST), and alanine transaminase (ALT)  
b ECG
s are to be done before ALT-[ADDRESS_442689] ALT-803 dose (Cycle 1, Week 1, Day1). As clinically indicated, ECGs are to be obtained to 
evaluate for cardiac toxicity during subsequent doses and cycles of therapy and follow-up visits.  
c Baseline tumor assessment scans should be done [ADDRESS_442690] may be done up to 48 hours before ALT-803 administration  
f See pharmacokinetic flow sheet for specific draw times 
g Blood for WB Immunophenotypi[INVESTIGATOR_007], IFN-γ ELISPOT, NK-cell function, plasma cytokines, Kyn/Trp ratio and serum Ab to ALT-[ADDRESS_442691] be done prior to starting 
th
erapy (Cycle 1, Day 1, Week 1) and repeated if clinically indicated (See Section 6.0  for additional details) .  
iAdditional cycles beyond the 4th cycle may be considered for patients continuing to benefit and tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
jOther labs include: Lactate dehydrogenase, magnesium, phosphate, CK and troponin I or T ; must be drawn before  and at [ADDRESS_442692] ALT-803 dose. 
kCBC w/diff, plts (Cycle 1, Week 1, Day 1); must be drawn before  and at [ADDRESS_442693] ALT-803 dose.  
NCI Protocol #: CITN -06-ALT-803  
Version Date: April 13, 2016 
 
1 
 NCI Protocol #:  CITN -06-ALT -803 
 
Local Protocol #: CA-ALT -803-01-13 
 TITLE:  A Phase 1  Study of the Clinical and Immunologic E ffects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head and Neck Cancer  
 
 
 Sponsor:  
      
 
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center  
 *Principal Investigator:  [INVESTIGATOR_355335], MD  
 Roswell Park Cancer Institute  
 Elm &  Carlton Streets  
 Buffalo, NY [ZIP_CODE] 
 ([PHONE_7383] 
 [EMAIL_6828]
 
    
Co-Principal Investigator:  [INVESTIGATOR_355332], MD 
 City of Hope 
 ([PHONE_7384] 
 [EMAIL_597]
 
   Co-Investigators: Lionel Lewis, MD 
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7375] 
 [EMAIL_603]
 
  
 Sylvia Lee, MD  
 Seattle Cancer Care Alliance  
 ([PHONE_7376] 
 [EMAIL_6817]  
  Shernan Holtan, MD  
 
 Hing C. Wong, Ph.D.  Altor Bioscience Corporation.  Miramar, [LOCATION_012] [ZIP_CODE]  Telephone: [PHONE_7260]  Safety Data Fax:  [PHONE_7261] 
  
NCI Protocol #: CITN -06-ALT-803  
Version Date: April 13, 2016 
 
2 
  University of Minnesota 
 ([PHONE_7377] 
 [EMAIL_6818]  
  
 
   Howard L. Kaufman, MD, FACS 
 Rutgers University  
 ([PHONE_7378] 
 [EMAIL_6819]
 
  
 Vamsidhar Velcheti, MD  
 Cleveland Clinic Foundation 
 ([PHONE_7382] 
 [EMAIL_6827]  
  
 Thomas Waldmann, MD 
 National Cancer Institute  
 ([PHONE_7372] 
 [EMAIL_6808]  
 The SCCA , Cleveland Clinic Foundation, UCSF , University of Minnesota and Rutgers 
University will participate to the dose -escalation phase of the trial. NCI will be added in the 
expansion phase of the trial. 
NCI Protocol #: CITN -06-ALT-803  
Version Date: April 13, 2016 
 
3 
 INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1 Study of the Clinical and 
Immunologic Effects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with 
Advanced Solid Tumors: Melanoma, Renal Cell, 
Non-Small Cell Lung and Squamous Cell Head 
and Neck Cancer   
   
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 Version # 05 Version # 06 Version # 07 Version # 08 Version # [ADDRESS_442694] 5, 2015 
 Version # [ADDRESS_442695]:  April 13, 2016  
 
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] Safety Data Fax:  [PHONE_7261] 
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read,  and that I understand and will abide by 
[CONTACT_22138], instructions, and restrictions contained in the attached protocol.  Additionally, I will not initiate this study without approval of the appropriate Institutional Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
 
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    
  

NCI Protocol #: CITN -06-ALT-803  
Version Date: April 13, 2016 
 
4 
 Statistician:  Study Coordinator: N/A  
Zoe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442696] N, Mail Stop M2-C200  
Seattle, WA [ZIP_CODE]   
 ([PHONE_7373]  
Fax: ([PHONE_7374]   
[EMAIL_6809]   
 
Responsible Research Nurse:  N/A  Responsible Data Manager: N/A  
   
NCI-Supplied Agent(s):  N/A  
 Other Agent(s ): ALT -803: a “recombinant human superagonist interleukin-15 (IL-15) complex” 
(AKA, IL -15N72D: IL-15RαSu/IgG1 Fc complex) NSC#: TBD  
   
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Amendment / Version 8.0 /March 31, 2016 
  
NCI Protocol #: CITN -06-ALT-803  
Version Date: April 13, 2016 
 
5 
 CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_293843]:  For patient enrollments:  Submit study data    
CTSU Regulatory Office  
[ADDRESS_442697] 
Philadelphia, PA [ZIP_CODE] 
Phone – 1-866-651- CTSU  
Fax – [PHONE_030] 
Email: 
[EMAIL_6814].o
rg (for submitting regulatory 
documents only) Please refer to the patient enrollment 
section for instructions on using the 
Oncology Patient Enrollment Network 
(OPEN ) at 
https://ww w.ctsu.org/OPEN_SYSTEM/  
or https://OPEN.ctsu.org . 
 
Contact [CONTACT_56112] -related questions at 
[EMAIL_013].  Data collection for this 
study will be done via  
Medidata Rave (Axio Research) .   
 Please see the data 
submission section of the protocol for further 
instructions.  
 
 
   
The current version of the study protocol and all supporting documents  must be downloaded from the 
protocol- specific Web page of the CTSU Member Web site located at https://www.ctsu.org .   
For patient eligibility or treatment -related questions:  
Contact [CONTACT_355337] [EMAIL_6815]  or [PHONE_7379] 
For questions unrelated to patient eligibility, treatment, or clinical data submission  contact [CONTACT_355339] e- mail:  
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
corresponden ce will be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at   https://www.ctsu.org  
 
  
NCI Protocol #: CITN -06-ALT-803  
Version Date: April 13, 2016 
 
6 
 SCHEMA  
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT-803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.3 μg/kg or  
0.5 μg/kg or 
1 μg/kg or 
3 μg/kg or 
6 μg/kg IV D1, W1  
D1, W2 
D1, W3 
D1, W4 42 days  
(4 weeks on, 2 weeks off)  
With up to 4 cycles in the 
absence of unacceptable 
toxicity and disease 
progression** 6 μg/kg  
10 μg/kg 
15 μg/kg 
20 μg/kg  SQ 
*Non- steroidal anti- inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thresholds:  
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours Ibuprofen: not to exceed 2400 mg in 24 hours Naproxen: not to exceed 1100 mg in 24 hours 
 ** Additional cycles beyond the 4
th cycle may be considered for patients continuing to benefit 
and tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
 
Dose Escalation Schedule  
Dose Level  Dose of ALT -803 Route of Administration  
Level -1 0.1 μg/kg (only if the first level is too toxic)  IV 
Level 1  0.3 μg/kg  IV 
Level 2  0.5 μg/kg  IV 
Level 3  1 μg/kg  IV 
Level 4  3 μg/kg  IV 
Level 5  6 μg/kg  IV 
Level 5a1 6 μg/kg  SQ 
Level 6  10 μg/kg  SQ 
Level 7  15 μg/kg  SQ 
Level 82 20 μg/kg  SQ 
1With protocol version #9, ALT -803 dosing is changed from IV to SQ, and dose level 5 is repeated to confirm safety 
with the new route of administration.  
2The dose of ALT -803 will be increased in increments of 5 μg/kg if a minimum of three patients have been  treated 
at dose level 8 (20 μg/kg), and the Maximum Tolerated Dose (MTD) and Optimum Biological Dose (OBD) have not 
been identified. Enrollment will continue until the MTD/OBD is identified.  
 
NCI Protocol #: CITN -06-ALT-803  
Version Date: April 13, [ADDRESS_442698] be performed within 30 days before the start of 
therapy. In the event that the patient’s condition is changing, laboratory evaluations should be repeated within 24 hours bef ore initiating the next cycle of 
therapy. Please refer to the study calendar below for specific timing of required evaluations. 
    F/U 
  Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442699] 
dose 6 
Mo 1  
yeari 
 Within 
30 days Within 
14 days Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1  Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1     D1±1  D4±1 D1±1  D4±1 
ALT -803*(A)    X  X X X   X  X X X      
Informed consent  X                   
Demographics  X                   
Medical history  X                   
Concomitant meds  X  X  X X X X X X  X X X X X X X X 
Physical examh  X X  X X X X  X  X X X X  X X X 
Vital signs with oxygen 
saturation   X X  X X X X X X  X X X X X X X X 
Height  X                   
Weight  X X X   X  X X X  X  X  X X X X 
Performance status   X X       X       X X X 
CBC w/diff, plts   X Xk X X X X X X X X X X X X X X X X 
PT/PTT   X                  
Serum chemistrya  X X  X X X X X X  X X X X X X X X 
Antinuclear antibody (ANA)  X         X        X X 
Electrocardiogram (ECG)b   X  X X X   X  X X X   X X X 
ECHO (as indicated)  X                   
Adverse event evaluation   X X  X X X X X X  X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 6 ± 1 week and 12 ± [ADDRESS_442700], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.    
CT or MRI Braind [as 
indicated for sympt only]  X If negative at baseline, to be repeated only with symptoms  X  
Radiologic evaluation by 
[CONTACT_393] 1.1  X Radiologic measurements should be performed every 6 ± 1 week and  12 ± 2 weeks  X  
NCI Protocol #: CITN -06-ALT-803  
Version Date: April 13, 2016 
 
63 
     F/U 
  Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442701] 
dose 6 
Mo 1  
yeari 
 Within 
30 days Within 
14 days Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1  Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1     D1±1  D4±1 D1±1  D4±1 
Injection Site Evaluation     X X X X   X X X X X   X   
B-HCGe   X                 
Thyroid studies: TSH, T4  X                 X X 
PKf    X                 
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X X  X X    X     
IFN-γ ELISPOTg   X     X  X          
NK-cell functiong   X X X   X  X X         
Plasma cytokinesg   X     X  X     X     
Kyn/Trp ratiog   X     X  X     X     
Serum Ab to ALT -803g   X       X       X   
Other laboratoriesj   X                 
Serum Storage (optional)    X     X            
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natur al killer; PET, positron emission tomo graphy; PK, 
pharmacokinetics; PT T, partial thromboplastin time; PT, prothrombin time  
*(A):  Agent  
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, alkaline phosphatase, aspartate 
transaminas e (AST), and alanine transaminase (ALT)  
b ECGs are to be done before ALT -[ADDRESS_442702] ALT -803 dose (Cycle 1, Week 1, Day1) . As clinically indicated, ECGs are to be obtained to 
evaluate for cardiac toxicity during  subsequent dose s and cycles of therapy  and follow -up visits .  
c Baseline tumor assessment scans should be done [ADDRESS_442703] may be done up to 48 hours before ALT -803 administration  
f See pharmacokinetic flow sheet for specific draw times  
g Blood for WB Immunophenotypi[INVESTIGATOR_007], IFN -γ ELISPOT, NK-cell function, plasma cytokin es, Kyn/Trp ratio  and serum Ab to ALT -[ADDRESS_442704] be done  prior to starting 
therapy  (Cycle 1, Day 1, Week 1)  and repeated if clinically indicated  (See Section 6.0  for additional details) .  
iAdditional cycles beyond the 4th cycle may be considered for patients continuing to benefit and tolerating therapy, upon discussion among the sponsor and Principal Investigator.  
jOther labs include: Lactate dehydrogenase, magnesium, phosphate, CK and troponin I  or T; must be drawn before and at [ADDRESS_442705] ALT -803 dose.  
kCBC w/diff, plts (Cycle 1, Week 1, Day 1); must be drawn before and at [ADDRESS_442706] ALT -803 dose.  
NCI Protocol #: CITN -06-ALT -803  
Version Date: August 9 , 2016 
 
1 
 NCI Protocol #:  CITN -06-ALT -803 
 
Local Protocol #: CA-ALT -803-01-13 
 TITLE:  A Phase 1  Study of the Clinical and Immunologic E ffects of ALT -803, a Novel 
Recombinant IL -15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, 
Sarcoma, Colon, Non -Hodgkin Lymphoma, Non -Small Cell Lung and Squamous Cell Head 
and Neck Cancer  and Cutaneous Squamous Cell Cancer  
 
 
 Sponsor:  
      
 
Coordinating Center:    Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center  
 *Principal Investigator:  [INVESTIGATOR_355335], MD  
 Roswell Park Cancer Institute  
 Elm & Carlton Streets  
 Buffalo, NY [ZIP_CODE] 
 ([PHONE_7383] 
 [EMAIL_6828]
 
    
Co-Principal Investigator:  [INVESTIGATOR_355332], MD 
 City of Hope 
 ([PHONE_7384] 
 [EMAIL_597]
 
  
 Jeffrey S. Miller  
 University of Minnesota  
 ([PHONE_7385] 
 [EMAIL_6829]  
 
Co-Investigators: Lionel Lewis, MD  
 Dartmouth Hitchcock Medical Center  
 ([PHONE_7375] 
 [EMAIL_603]  
  
   
  
 Hing C. Wong, Ph.D. 
 Altor Bioscience Corporation.  Miramar, [LOCATION_012] [ZIP_CODE]  Telephone: [PHONE_7260]  Safety Data Fax:  [PHONE_7261] 
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: August 9 , 2016 
 
2 
  Sylvia Lee, MD  
 Seattle Cancer Care Alliance  
 ([PHONE_7376] 
 [EMAIL_6817]  
 
 Shernan Holtan, MD 
 University of Minnesota 
 ([PHONE_7377] 
 [EMAIL_6818]  
  
 Howard L. Kaufman, MD, FACS 
 Rutgers University  
 ([PHONE_7378] 
 [EMAIL_6819]  
  
 Vamsidhar Velcheti, MD  
 Cleveland Clinic Foundation 
 ([PHONE_7382] 
 [EMAIL_6827]  
  
 Thomas Waldmann, MD 
 National Cancer Institute  
 ([PHONE_7372] 
 [EMAIL_6808]  
 The SCCA , Cleveland Clinic Foundation, University of Minnesota and Rutgers University will 
participate to the dose- escalation phase of the trial. NCI will be added in the expansion phase of 
the trial. 
NCI Protocol #: CITN -06-ALT -803  
Version Date: August 9 , 2016 
 
3 
 INVESTIGATOR SIGNATURE [CONTACT_118258]:  CA-ALT -803-01-13 
  
Protocol Title:  A Phase 1 Study of the Clinical and Immunologic Effects 
of ALT -803, a Novel Recombinant IL-15 Complex in 
Patients with Advanced Solid Tumors: Melanoma, Renal 
Cell,  Sarcoma, Colon, Non-Hodgkin Lymphoma,   Non -
Small Cell Lung and Squamous Cell Head and Neck Cancer  and Cutaneous Squamous Cell Cancer  
   
Date of Protocol:   
Version # 01  
Version # 02 
Version # 03 Version # 04 Version # 05 Version # 06 Version # 07 Version # 08 Version # [ADDRESS_442707] 5, 2015 
 Version # 10  
Version # [ADDRESS_442708]:  April 13, [ADDRESS_442709] 9, 2016  
 
Hing C. Wong, Ph.D. Altor Bioscience Corporation. Miramar, [LOCATION_012] [ZIP_CODE] Telephone: [PHONE_7260] 
Safety Data Fax: [PHONE_7261]  
 By [CONTACT_12006], I hereby [CONTACT_22052] I have read, and that I understand and will abide by [CONTACT_22138], instructions, and restrictions contained in the attached protocol.  Additionally, I will not initiate this study withou t approval of the appropriate Institutional 
Review Board (IRB), and I understand that any changes in the protocol must be approved in writing by [CONTACT_456], the IRB, and, in certain cases the FDA, before they can be implemented, except where necessary to eliminate hazards to subjects.  
 
   
Principal Investigator’s Signature   [CONTACT_351125]’s Name (Print)    

NCI Protocol #: CITN -06-ALT -803  
Version Date: August 9 , 2016 
 
4 
  
Statistician:  Study Coordinator: N/A  
Zoe Moodie, PhD  
Fred Hutchinson Cancer Research Center   
[ADDRESS_442710] N, Mail Stop M2-C200  Seattle, WA [ZIP_CODE]   
 ([PHONE_7373]  
Fax: ([PHONE_7374]   
[EMAIL_6809]   
 
Responsible Research Nurse:  N/A  Responsible Data Manager: N/A  
   
NCI-Supplied Agent(s):  N/A  
 Other Agent(s ): ALT -803: a “recombinant human superagonist interleukin-15 (IL-15) complex” 
(AKA, IL -15N72D: IL-15RαSu/IgG1 Fc complex) NSC#: TBD  
   
Investigational Agent  IND#  IND Sponsor  
ALT -803 118280  Altor Bioscience Corporation  
 
Protocol Type / Version # / Version Date:  Amendment  9 /Version 2.0 /July 13, 2016 
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: August 9 , 2016 
 
5 
 CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_293843]:  For patient enrollments:  Submit study data    
CTSU Regulatory Office  
[ADDRESS_442711] 
Philadelphia, PA [ZIP_CODE] 
Phone – 1-866-651- CTSU  
Fax – [PHONE_030] 
Email: 
[EMAIL_6814].o
rg (for submitting regulatory 
documents only) Please refer to the patient enrollment 
section for instructions on using the 
Oncology Patient Enrollment Network 
(OPEN ) at 
https://www.ctsu.org/OPEN_SYSTEM/  
or https://OPEN.ctsu.org . 
 
Contact [CONTACT_56112] -related questions at 
ctsucont [EMAIL_6830].  Data collection for this 
study will be done via  
Medidata Rave (Axio Research) .   
 Please see the data 
submission section of the protocol for further 
instructions.  
 
 
   
The current version of the study protocol and all supporting documents  must be downloaded from the 
protocol- specific Web page of the CTSU Member Web site located at https://www.ctsu.org .   
For patient eligibility or treatment -related questions:  
Contact [CONTACT_355337] [EMAIL_6815]  or [PHONE_7379] 
For questions unrelated to patient eligibility, treatment, or clinical data submission  contact [CONTACT_355339] e- mail:  
CTSU General Information Line – [PHONE_031], or [EMAIL_013] .  All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU Web site is located at   https://www.ctsu.org  
 
  
NCI Protocol #: CITN -06-ALT -803  
Version Date: August 9 , 2016 
 
6 
 SCHEMA  
 
Regimen Description  
Agent  Pre-Medications:  
Precautions  Dose  Route  Schedule  Cycle Length  
ALT -803 *1 dose of 
antipyretic 
medication within 
30 min of ALT-803 
administration  
 
*1 dose of 
antipyretic 
medication 4 h after 
ALT -803 
administration  0.3 μg/kg or  
0.5 μg/kg or 
1 μg/kg or 
3 μg/kg or 
6 μg/kg IV D1, W1  
D1, W2 
D1, W3 
D1, W4 42 days  
(4 weeks on, 2 weeks off)  
With up to 4 cycles in the 
absence of unacceptable 
toxicity and disease 
progression** 6 μg/kg  
10 μg/kg 
15 μg/kg 
20 μg/kg  SQ 
  10 µg/kg + 
15 µg/kg SQ  
15 µg/kg +  
15 µg/kg SQ 
20 µg/kg + 
15 µg/kg SQ IT 
followed 
by [INVESTIGATOR_45220]  D1, W1 
(IT) 
D1, W2 
(SQ)  
D1, W3 
(SQ)  
D1, W4 
(SQ)  42 days  
(4 weeks on, 2 weeks off)  
With up to 4  cycles in the 
absence of unacceptable 
toxicity and disease 
progression** 
 
Cycle 1 only: pre and 
post treatment biopsy  
*Non- steroidal anti- inflammatory medication including agents such as acetaminophen, 
ibuprofen, or Naproxen may be given per physician discretion. Not to exceed standard maximum 
thresholds:  
Acetaminophen: not to exceed 3000 mg (3 g) in 24 hours Ibuprofen: not to exceed 2400 mg in 24 hours Naproxen: not to exceed 1100 mg in 24 hours 
 ** Additional cycles beyond the 4
th cycle may be considered for patients continuing to benefit 
and tolerating therapy, upon discussion among the sponsor and Principal Investigator. 
 
Dose Escalation Schedule  
Cohort 1  
Dose Level  Dose of ALT -803 Route of Administration  
Level -1 0.1 μg/kg (only if the first level is too toxic)  IV 
Level 1  0.3 μg/kg  IV 
Level 2  0.5 μg/kg  IV 
Level 3  1 μg/kg  IV 
Level 4  3 μg/kg  IV 
Level 5  6 μg/kg  IV 
Cohort 23 
NCI Protocol #: CITN -06-ALT -803  
Version Date: August 9 , 2016 
 
7 
 Level 5a1 6 μg/kg  SQ 
Level 6  10 μg/kg  SQ 
Level 7  15 μg/kg  SQ 
Level 82 20 μg/kg  SQ 
Cohort 33,4 
Level 1  10 µg/kg  IT (Week 1)  
15 µg/kg  SQ (Week 2, 3, 4)  
Level 2  15 µg/kg  IT (Week 1)  
15 µg/kg  SQ (Week 2, 3, 4)  
Level 32 20 µg/kg  IT (Week 1)  
15 µg/kg  SQ (Week 2, 3, 4)  
1With protocol version #9, ALT -803 dosing is changed from IV to SQ,  and dose level 5 is repeated to confirm safety 
with the new route of administration.  
2The dose of ALT -803 will be increased in increments of 5 μg/kg if a minimum of three patients have been treated 
at dose level 8  in Cohort 2 or dose level 3 in Cohort 3, and the Maximum Tolerated Dose (MTD) and Optimum 
Biological Dose (OBD) have not been identified. Enrollment will continue until the MTD/OBD is identified.  
3Cohort 2 and Cohort 3 enrollment will occur in parallel. The treatment cohort assignment  (Cohort 2 vs Cohort 
3) is at the Investigator and patient discretion. Cohort [ADDRESS_442712] -treatment biopsy.  
4Cohort 3, dose escalation only for the IT portion; SQ  dose remains constant at 15 µg/kg.  
 
NCI Protocol #: CITN -06-ALT -803  
Version Date: August [ADDRESS_442713] be performed within 30 days before the start of 
therapy. In the event that the patient’s condition is changing, laboratory evaluations should be repeated within 24 hours bef ore initiating the next cycle of 
therapy. Please refer to the study calendar below for specific timing of required evaluations. 
    F/U 
  Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442714] 
dose 6 
Mo 1  
yeari 
 Within 
30 days Within 
14 days Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1  Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1     D1±1  D4±1 D1±1  D4±1 
ALT -803   Xl  X X X   Xl  X X X      
Informed consent  X                   
Demographics  X                   
Medical history  X                   
Concomitant meds  X  X  X X X X X X  X X X X X X X X 
Physical examh  X X  X X X X  X  X X X X  X X X 
Vital signs with oxygen 
saturation   X X  X X X X X X  X X X X X X X X 
Height  X                   
Weight  X X X   X  X X X  X  X  X X X X 
Performance status   X X       X       X X X 
CBC w/diff, plts   X Xk X X X X X X X X X X X X X X X X 
PT/PTT   X                  
Serum chemistrya  X X  X X X X X X  X X X X X X X X 
Antinuclear antibody (ANA)  X         X        X X 
Electrocardiogram (ECG)b   X  X X X   X  X X X   X X X 
ECHO (as indicated)  X                   
Adverse event evaluation   X X  X X X X X X  X X X X X X X X 
Tumor measurementsc X Tumor measurements are repeated every 6 ± 1 week and 12 ± [ADDRESS_442715], 
abdomen, pelvisd X Documentation (radiologic) must be provided for patients removed from study for progressive disease.    
CT or MRI Braind [as 
indicated for sympt only]  X If negative at baseline, to be repeated only with symptoms  X  
Radiologic evaluation by 
[CONTACT_393] 1.1  X Radiologic measurements should be performed every 6 ± 1 week and  12 ± 2 weeks  X  
NCI Protocol #: CITN -06-ALT -803  
Version Date: August 9 , 2016 
 
69 
     F/U 
  Pre-study  
(screening)  Cycle 1 (Weeks)  Cycle 2 (Weeks)  [ADDRESS_442716] 
dose 6 
Mo 1  
yeari 
 Within 
30 days Within 
14 days Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1  Week 1  W2 
D8±1  W3 
D15±1  W4 
D22±1  W5 
D29±1  W6 
D36±1     D1±1  D4±1 D1±1  D4±1 
Injection Site Evaluation     X X X X   X X X X X   X   
B-HCGe   X                 
Thyroid studies: TSH, T4  X                 X X 
PKf    X                 
WB Immunophenotypi[INVESTIGATOR_355334]   X X X X X X  X X    X     
IFN-γ ELISPOTg   X     X  X          
NK-cell functiong   X X X   X  X X         
Plasma cytokinesg   X     X  X     X     
Kyn/Trp ratiog   X     X  X     X     
Serum Ab to ALT -803g   X       X       X   
Other laboratoriesj   X                 
Serum Storage (optional)    X X                
Biopsym   X  X               
Abbreviations: Ab, antibodies; CBC, complete blood count; CT, computed tomography; MRI, magnetic resonance imaging; NK, natur al killer; PET, positron emission tomo graphy; PK, 
pharmacokinetics; PT T, partial thromboplastin time; PT, prothrombin time  
a Blood chemistries include: creatinine, glucose, total protein, blood urea nitrogen (BUN), total carbon dioxide (CO 2), albumin, total bilirubin, phosphorus, alkaline phosphatase, aspartate 
transaminas e (AST), and alanine transaminase (ALT)  
b ECGs are to be done before ALT -[ADDRESS_442717] ALT -803 dose (Cycle 1, Week 1, Day1) . As clinically indicated, ECGs are to be obtained to 
evaluate for cardiac toxicity during  subsequent dose s and cycles of therapy  and follow -up visits .  
c Baseline tumor assessment scans should be done [ADDRESS_442718] may be done up to 48 hours before ALT -803 administration  
f See pharmacokinetic flow sheet for specific draw times  
g Blood for WB Immunophenotypi[INVESTIGATOR_007], IFN -γ ELISPOT, NK-cell function, plasma cytokin es, Kyn/Trp ratio  and serum Ab to ALT -[ADDRESS_442719] be done  prior to starting 
therapy  (Cycle 1, Day 1, Week 1)  and repeated if clinically indicated  (See Section 6.0  for additional details) .  
iAdditional cycles beyond the 4th cycle may be considered for patients continuing to benefit and tolerating therapy, upon discussion among the sponsor and Principal Investigator.  
jOther labs include: Lactate dehydrogenase, magnesium, phosphate, CK and troponin I  or T; must be drawn before and at [ADDRESS_442720] ALT -803 dose.  
kCBC w/diff, plts (Cycle 1, Week 1, Day 1); must be drawn before and at [ADDRESS_442721] ALT -803 dose.  
lCohort 3 only, intratumoral injection (Week 1, Day 1 of each treatment cycle)  
mCohort [ADDRESS_442722] be done before ALT -803 administration  